
<html lang="en"     class="pb-page"  data-request-id="aa7f2011-c709-44dc-869e-1f1831fc49bb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-24;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01611"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia" /></meta><meta name="dc.Creator" content="Xixiang  Li" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Hong  Wu" /></meta><meta name="dc.Creator" content="Jiaxin  Wu" /></meta><meta name="dc.Creator" content="Zheng  Zhao" /></meta><meta name="dc.Creator" content="Juan  Liu" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Shanchun  Zhang" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Description" content="FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor tha..." /></meta><meta name="Description" content="FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor tha..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 14, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01611" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01611" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01611" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01611" /></link>
        
    
    

<title>Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01611" /></meta><meta property="og:title" content="Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0012.jpeg" /></meta><meta property="og:description" content="FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, we have discovered compound 18 (CHMFL-FLT3-122), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold). It significantly inhibited the proliferation of FLT3-ITD positive AML cancer cell lines MV4-11 (GI50 = 22 nM), MOLM13/14 (GI50 = 21 nM/42 nM). More importantly, 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GI50 = 11 nM versus 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity. In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase. In the in vivo studies 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity. Compound 18 might be a potential drug candidate for FLT3-ITD positive AML." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01611"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01611">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01611&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01611&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01611&amp;href=/doi/10.1021/acs.jmedchem.5b01611" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 9625-9638</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01456" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01283" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xixiang++Li">Xixiang Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Wu">Hong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiaxin++Wu">Jiaxin Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Zhao">Zheng Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Liu">Juan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shanchun++Zhang">Shanchun Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Science and Technology of China, Hefei 230036, Anhui, P. R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Hefei Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei 230031, Anhui, P. R. China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Hefei Science Center, Chinese Academy of Sciences, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div><div class="corresp-info"><strong>*</strong>J.L.: e-mail, <a href="/cdn-cgi/l/email-protection#7f1516111813160a3f17121913511e1c511c11"><span class="__cf_email__" data-cfemail="741e1d1a13181d01341c1912185a15175a171a">[email protected]</span></a>; phone, (+86) 551-65593186.</div><div class="corresp-info"><strong>*</strong>Q.L.: e-mail, <a href="/cdn-cgi/l/email-protection#29585a45405c101e6941444f4507484a074a47"><span class="__cf_email__" data-cfemail="2e5f5d42475b17196e46434842004f4d004d40">[email protected]</span></a>; phone, (+86) 551-65595161.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01611&amp;href=/doi/10.1021%2Facs.jmedchem.5b01611" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 9625–9638</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 2, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 August 2015</li><li><span class="item_label"><b>Published</b> online</span>14 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01611" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01611</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9625%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXixiang%2BLi%252C%2BAoli%2BWang%252C%2BKailin%2BYu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D24%26contentID%3Dacs.jmedchem.5b01611%26title%3DDiscovery%2Bof%2B%2528R%2529-1-%25283-%25284-Amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2B%2528CHMFL-FLT3-122%2529%2Bas%2Ba%2BPotent%2Band%2BOrally%2BAvailable%2BFLT3%2BKinase%2BInhibitor%2Bfor%2BFLT3-ITD%2BPositive%2BAcute%2BMyeloid%2BLeukemia%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9638%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01611"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4369</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01611" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xixiang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Jiaxin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shanchun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9625-9638&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01611&quot;},&quot;abstract&quot;:&quot;FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, we have discovered compound 18 (CHMFL-FLT3-122), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold). It significantly inhibited the proliferation of FLT3-ITD positive AML cancer cell lines MV4-11 (GI50 = 22 nM), MOLM13/14 (GI50 = 21 nM/42 nM). More importantly, 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GI50 = 11 nM versus 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity. In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase. In the in v&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01611&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01611" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01611&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01611" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01611&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01611" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01611&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01611&amp;href=/doi/10.1021/acs.jmedchem.5b01611" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01611" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01611" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26pmid%3D26630553%26genre%3Darticle%26aulast%3DLi%26date%3D2015%26atitle%3DDiscovery%2Bof%2B%2528R%2529-1-%25283-%25284-Amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2B%2528CHMFL-FLT3-122%2529%2Bas%2Ba%2BPotent%2Band%2BOrally%2BAvailable%2BFLT3%2BKinase%2BInhibitor%2Bfor%2BFLT3-ITD%2BPositive%2BAcute%2BMyeloid%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D24%26spage%3D9625%26epage%3D9638%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/jmcmar.2015.58.issue-24/20151224/jmcmar.2015.58.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, we have discovered compound <b>18</b> (CHMFL-FLT3-122), which displayed an IC<sub>50</sub> of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold). It significantly inhibited the proliferation of FLT3-ITD positive AML cancer cell lines MV4-11 (GI<sub>50</sub> = 22 nM), MOLM13/14 (GI<sub>50</sub> = 21 nM/42 nM). More importantly, <b>18</b> demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GI<sub>50</sub> = 11 nM versus 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity. In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase. In the in vivo studies <b>18</b> demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity. Compound <b>18</b> might be a potential drug candidate for FLT3-ITD positive AML.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute myeloid leukemia (AML) accounts for approximately 80–90% of leukemia in adults. Over 10 000 new AML patients are diagnosed and lead to similar number of deaths per year in U.S. alone.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The current standard chemotherapy for AML usually lacks the durable efficacy and is also poorly tolerated especially in the elder patients. FMS-like tyrosine kinase (FLT3) is a type III receptor tyrosine kinase that plays important roles in the differentiation and survival of hematopoietic stem cells in bone marrow and has been observed overexpressed in the AML and ALL.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> A variety of gain-of-function mutations have been identified in the AML patients such as FLT3-ITD (internal tandem duplication), FLT3-D835Y/E/V/H, and FLT3-K663Q, etc., among which FLT3-ITD accounts for about 30% and is associated with poor prognosis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The mutated FLT3-ITD kinase promotes the AML blast survival and proliferation through the downstream signaling mediators including Stat5, ERK, and AKT.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, FLT3-ITD kinase has been considered as a validated drug discovery target for FLT3-ITD positive AML.</div><div class="NLM_p">A number of small molecule inhibitors have been reported to exhibit potent FLT3 kinase inhibitory activities such as sunitinib,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> sorafenib,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> PKC412,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> CEP-701,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> UNC2025,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> MLN518,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> KW-2449,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and AMG-925,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> etc. In addition, the relatively more selective second generation FLT3 inhibitors such as AC220,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> crenolanib,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and PLX3397<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> are being tested in the clinic now and have shown initial transient responses but usually followed by quick development of resistance. Besides, the c-KIT kinase and FLT3 kinase dual inhibition induced synthetic lethal myelosuppression toxicity observed from the most advanced clinical trial compounds such as PKC412 and AC220 is also a big safety concern.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Currently there is no FLT3 targeted therapies getting approved for clinical application yet.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Hence, there is still a critical unmet medical need remaining for FLT3-ITD positive AML.</div><div class="NLM_p">Recently we discovered that PCI-32765 (<b>1</b>), a clinically used BTK kinase inhibitor for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), also displayed submicromolar GI<sub>50</sub> against FLT3-ITD positive AML cancer cell lines.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> In addition, compound <b>1</b> did not exhibit apparent c-KIT kinase inhibition which indicated a better safety profile for this class of compounds. In order to further improve the FLT3 kinase potency and selectivity of this new class of compounds, starting from <b>1</b>, through a detailed SAR study, we discovered a potent, selective, and orally available FLT3 kinase inhibitor <b>18</b> (CHMFL-FLT3-122) that displayed impressive in vitro and in vivo activities against FLT3-ITD positive AML (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemcial structures of PCI-32765 (<b>1</b>) and CHMFL-FLT3-122 (<b>18</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discusstion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25368" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25368" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We first examined the binding mode of PCI-32765 to BTK and FLT3 kinase in order to direct the chemical modification (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In BTK kinase, PCI-32765 forms three hydrogen bonds with Met477, Glu475, and Thr474, respectively, in the hinge binding area. The signature of this binding is that the acrylamide of PCI-32765 forms a covalent bond with Cys481 to achieve the irreversible binding. The O-bridged diphenyl moiety directs into the hydrophobic pocket formed by DFG motif and α-cHelix (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). In comparison, PCI-32765 forms two similar hydrogen bonds with Cys694 and Glu692 of FLT3 kinase in the hinge binding area. However, the Cys481 in BTK is replaced by Asp698 in FLT3 which makes the irreversible binding impossible (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). Superimposition of BTK and FLT3 kinase reveals that the Phe830 in the DFG motif of FLT3 kinase (white in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C) flips more flat than Phe540 in BTK kinase (purple in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C), which might provide more space for this hydrophobic pocket. However, the α-cHelix of FLT3 kinase shifts closer to the hinge binding area than the α-cHelix of BTK kinase; hence, this will shrink the hydrophobic pocket (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). Combining all of the analyses, we proposed that there are two directions we can take to improve the binding affinity for new lead compounds against FLT3 kinase. First, we can modify the O-bridged diphenyl group (R2, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>D) to investigate if there is a larger pocket created by α-cHelix-in and Phe830-out. Second, since in FLT3 kinase there is no approachable cysteine residue required by irreversible binding, we can modify the piperidine acrylamide moiety (R1 and R3, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>D) to achieve better selectivity and stronger binding affinity against FLT3 kinase.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode analysis of PCI-32765 (<b>1</b>) to BTK kinase and FLT3 kinase. (A) PCI-32765 docked into BTK kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>). (B) PCI-32765 docked into FLT3 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>). (C) Superimposition of BTK and FLT3 kinase in complex with PCI-32765 (purple, BTK kinase; white, FLT3 kinase). (D) Illustration of the chemical modification strategy of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first made compound <b>2</b> which bears a double bond linked diphenyl moiety to explore the possibility of FLT3 kinase occupying a larger inner hydrophobic pocket formed by DFG motif and α-cHelix. However, compared with <b>1</b>, it significantly lost the activity against intact AML cancer cell line MV4-11 (GI<sub>50</sub> of 10 μM versus 0.33 μM) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), which expresses the FLT3-ITD mutant. In the isogenic BaF3 cells whose proliferation is dependent on FLT3-ITD, compound <b>2</b> also lost about 15-fold activity (GI<sub>50</sub> of 1.8 μM versus 0.12 μM). This indicated that FLT3 might not tolerate the larger hydrophobic moiety. We then turned our attention to the hinge binding area and made a series of modifications at R1 position to explore the SAR. Since there is no approachable cysteine residue which could be utilized to form the covalent bond as in BTK kinase, we first saturated the double bond in <b>1</b> to make <b>3</b> and found that it exhibited better inhibitory activities against MV4-11 (GI<sub>50</sub> = 0.13 μM) and FLT3-ITD-BaF3 isogenic cell line (GI<sub>50</sub> = 0.028 μM). But it also displayed a GI<sub>50</sub> of 3.8 μM against parental BaF3 cell line which indicated that there was still selectivity window that could be explored (ideally, the compound that does not show apparent inhibitory activity against the parental BaF3 cells; i.e., >10 μM is preferred). Variation of terminal ethyl group, methyl group (<b>4</b>), or bulky ones such as propyl (<b>5</b>), <i>tert</i>-butyl (<b>6</b>), 2-methylbutyl (<b>7</b>), dimethylpropyl (<b>8</b>), and cyclopropyl (<b>9</b>) all led to significant lose of inhibitory activity. However, introduction of the methylcyclopropyl group (<b>10</b>) started to gain back the activity against MV4-11 (GI<sub>50</sub> = 0.41 μM) and FLT3-ITD-BaF3 cells (GI<sub>50</sub> = 0.082 μM), though still weaker than <b>3</b>. Methylpiperidine (<b>11</b>) and 1,4-dimethylpiperazine (<b>12</b>) exhibited comparably moderate activities to <b>3</b>. Compounds that switch the linking carbonyl group into sulfonamide and bear different sizes of substitutes (<b>13</b>–<b>15</b>) did not improve the antiproliferation efficacy either, despite all of them still having moderate potencies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Compounds <b>1</b>–<b>15</b> with Different Substituents at R1/R2 Position and Their Antiproliferation Efficacies against Intact and Isogenic Cancer Cell Lines<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">We then went back to analyze the binding mode again and envisioned that the Asp698 might serve as a hydrogen bond acceptor. If the substitutes at proper R1 position could provide a hydrogen bond donor, then it might increase the potency. Therefore, we replaced the acrylamide group with a series of amino acids and derivatives for SAR study. The glycine moiety (<b>16</b>) remarkably improved the antiproliferation efficacy against MV4-11 (GI<sub>50</sub> = 0.022 μM) and BaF3-FLT3-ITD (GI<sub>50</sub> = 0.007 μM) while still having proper selectivity against parental BaF3 cell (GI<sub>50</sub> = 3.8 μM) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), while the β-alanine (<b>17</b>) lost over 30-fold activity against MV4-11. The <i>N</i>,<i>N</i>-dimethylglycine (<b>18</b>) kept the activity against MV4-11 (GI<sub>50</sub> = 0.022 μM) and BaF3-FLT3-ITD (GI<sub>50</sub> = 0.011 μM) and showed better selectivity against parental BaF3 (GI<sub>50</sub> = 4.9 μM). Introduction of other amino acids, e.g., alanine (<b>19</b>), serine (<b>20</b>), valine (<b>21</b>), threonine (<b>22</b>), and leucine (<b>24</b>), led to similar activities except that isoleucine (<b>23)</b> lost around 6-fold activity. These results indicated that the hydrogen bond formed between Asp698 and the nitrogen atom in R1 was critical for the binding (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Compounds <b>16</b>–<b>24</b> with Amino Acids and Derivatives at R1 Position and Their Antiproliferation Efficacies<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>18</b> docked into FLT3 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since compound <b>18</b> displayed the best activities so far, we then placed more efforts to investigate the R3 part. Inversion of the <i>R</i> stereocenter on the piperidine ring of <b>18</b> to <i>S</i> (<b>25</b>) resulted in over 10-fold loss of activity, indicating that the <i>R</i> conformation was preferred at this position (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Shifting the amide moiety from 3-position of piperidine to 4-position (<b>26</b>–<b>28</b>) or replacing the piperidine ring by the pyrrolidine ring (<b>29</b>–<b>32</b>) all led to activity loss.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferation Efficacies of Compounds <b>25</b>–<b>32</b> Bearing Different R1 and R3 Moieties<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0011.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">Considering the potent antiproliferation activities against FLT3-ITD positive cell line and the selectivity window between the FLT3-ITD-BaF3 cell and parental BaF3 cell, we decided to choose <b>18</b> for further characterization. We first examined compound <b>18</b>’s selectivity with DiscoveRx’s KinomeScan technology. The results showed that compound <b>18</b> was very selective (S score (1) = 0.03 at 1 μM). Besides FLT3wt and FLT3/ITD, it also displayed strong binding against BLK, BTK, ERBB3, HCK, LCK, MEK5, PDGFRα, RET, and SRMS kinases (percent activity remaining less than 1% at 1 μM). (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A and <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01611/suppl_file/jm5b01611_si_001.xlsx" class="ext-link">Supporting Information Table 1</a>). Given the fact that KinomeScan is a binding assay and may not fully reflect the inhibitory activity, we then used ADP-Glo based biochemical activity assay with the purified kinase proteins to confirm compound <b>18</b>’s inhibition activity against FLT3, BTK, and c-KIT. The results demonstrated that compound <b>18</b> inhibited FLT3 kinase with an IC<sub>50</sub> of 40 nM (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). It also demonstrated a good selectivity over BTK kinase (IC<sub>50</sub> = 421 nM) and c-KIT kinase (IC<sub>50</sub> = 559 nM). We also used TEL transformed BaF3 system to further confirm the on-target activity and selectivity against other potential off-targets revealed by KinomeScan binding assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Interestingly, compound <b>18</b> was also very potent against FLT3-D835Y/V/H mutants, which are other important oncogenic mutations in the AML, in the BaF3 isogenic cell lines, while for the drug resistance mutations such as FLT3-ITD-D835Y, FLT3-ITD-F691L, it lost 16- to 20-fold activity compared to FLT3-ITD itself. In addition, <b>18</b> also exhibited good selectivity over c-Kit kinase (GI<sub>50</sub> of 1.9 μM versus 0.011 μM for FLT3-ITD, 170-fold selectivity) and other protein kinases such as MET, EGFR, JAK1/2/3, RET, PDGFRα, and BMX (around 25- to 200-fold) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In the SRC kinase family, compound <b>18</b> did not potently inhibit HCK (GI<sub>50</sub> = 0.88 μM), LCK (GI<sub>50</sub> = 0.31 μM), and BLK (GI<sub>50</sub> = 0.94 μM). Combining the results from all of these different assay formats, we concluded that compound <b>18</b> is a highly potent FLT3 kinase inhibitor. Compound <b>18</b> displayed similar potencies in the FLT3-ITD dependent AML cancer cell line MOLM13 (GI<sub>50</sub> = 0.021 μM) and MOLM14 (0.042 μM) as in MV4-11 (<a class="ref internalNav" href="#tbl5" aria-label="Tables 5">Tables 5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). As expected, it did not exhibit potent inhibitory activities against FLT3 wt or negative intact cancer cell lines such as U937, SU-DHL-2, U2932, JVM-2, Namalwa, and NB4 cell lines.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity profiling of compound <b>18</b>. (A) KinomeScan profiling of compound <b>18</b> at a concentration of 1 μM against 468 kinases. (B) Kinases showed strong binding to compound 18 (less than 1% activity remaining comparing to DMSO control in the assay format with 1 μM <b>18</b>). (C) ADP-Glo biochemical characterization of compound <b>18</b> against FLT3 kinase, BTK kinase, and c-KIT kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferation Effects of Compound <b>18</b> against a Variety of Isogenic BaF3 Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-FLT3 wt</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-c-KIT</td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FLT3-ITD-D835Y</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-MET</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FLT3-ITD-F691L</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-EGFR</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FLT3-D835Y</td><td class="colsep0 rowsep0" align="left">0.033</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-JAK1</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FLT3-D835V</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-JAK2</td><td class="colsep0 rowsep0" align="left">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-FLT3-D835H</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-JAK3</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-BLK</td><td class="colsep0 rowsep0" align="left">0.94</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-BMX</td><td class="colsep0 rowsep0" align="left">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-LCK</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-HCK</td><td class="colsep0 rowsep0" align="left">0.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-RET</td><td class="colsep0 rowsep0" align="left">0.65</td><td class="colsep0 rowsep0" align="left">BaF3-TEL-PDGFRb</td><td class="colsep0 rowsep0" align="left">0.68</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferation Effects of Compound <b>18</b> against a Variety of Intact Cancer Cell Lines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLM13</td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">U2932</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLM14</td><td class="colsep0 rowsep0" align="left">0.042</td><td class="colsep0 rowsep0" align="left">JVM-2</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="left">9.7</td><td class="colsep0 rowsep0" align="left">Namalwa</td><td class="colsep0 rowsep0" align="left">6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SU-DHL-2</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">NB4</td><td class="colsep0 rowsep0" align="left">3.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing</p></div></div></div><div class="NLM_p">We then investigated the inhibitory effect of <b>18</b> on FLT3 mediated signaling pathway. It significantly affected FLT3 autophosphorylation at Tyr589/591 site in MV4-11 and MOLM14 cell line (EC<sub>50</sub> less than 30 nM) as well as MOLM13 cell line (EC<sub>50</sub> about 100 nM) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). FLT3 kinase downstream mediator Stat5’s phosphorylation was also remarkably inhibited in these cell lines (EC<sub>50</sub> less than 30 nM). In addition, the phosphorylation of ERK, AKT and expression of cMYC were also significantly inhibited, which exhibited a similar trend compared to the well-established FLT3 inhibitor AC220. Compound <b>18</b> could also arrest cell cycle progression of these cell lines into the G0/G1 phase and induction of apoptosis (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>18</b> inhibited FLT3 kinase mediated signaling pathway in MV4-11, MOLM13, and MOLM14 cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>18</b> arrested cell cycle progression and induction of apoptosis in MV4-11, MOML14, and MOLM13 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also evaluated compound <b>18</b>’s PK properties in rats following intravenous and oral administration (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). The half-life of the <b>18</b> was about 1.4 h with iv and 1.2 h with po, and the bioavailability was about 30%. Overall it had a good volume distribution but relatively quick clearance.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK properties of Compound <b>18</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–t)</sub> (ng mL<sup>–1</sup> h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–∞)</sub> (ng mL<sup>–1</sup> h)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>z</sub> (mL/kg)</th><th class="colsep0 rowsep0" align="center">CL<sub>z</sub>, (mL h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">MRT<sub>(0–∞)</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv (1 mg/kg), mean</td><td class="colsep0 rowsep0" align="left">1.38</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left">1503.83</td><td class="colsep0 rowsep0" align="left">606.89</td><td class="colsep0 rowsep0" align="left">619.33</td><td class="colsep0 rowsep0" align="left">3233.38</td><td class="colsep0 rowsep0" align="left">1616.20</td><td class="colsep0 rowsep0" align="left">1.15</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">0.00</td><td class="colsep0 rowsep0" align="left">121.81</td><td class="colsep0 rowsep0" align="left">20.78</td><td class="colsep0 rowsep0" align="left">23.28</td><td class="colsep0 rowsep0" align="left">779.55</td><td class="colsep0 rowsep0" align="left">62.03</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po (10 mg/kg), mean</td><td class="colsep0 rowsep0" align="left">1.24</td><td class="colsep0 rowsep0" align="left">1.67</td><td class="colsep0 rowsep0" align="left">458.24</td><td class="colsep0 rowsep0" align="left">1834.84</td><td class="colsep0 rowsep0" align="left">1883.80</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2.75</td><td class="colsep0 rowsep0" align="left">30.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD</td><td class="colsep0 rowsep0" align="left">0.24</td><td class="colsep0 rowsep0" align="left">0.58</td><td class="colsep0 rowsep0" align="left">103.77</td><td class="colsep0 rowsep0" align="left">360.99</td><td class="colsep0 rowsep0" align="left">378.29</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table></div></div><div class="NLM_p">We next tested the antitumor efficacy of compound <b>18</b> in MV4-11 cell inoculated xenograft mouse model. With oral gavage, the 12.5, 25, and 50 mg kg<sup>–1</sup> day<sup>–1</sup> administration did not significantly affect the mice body weight (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). However, the 25 mg kg<sup>–1</sup> day<sup>–1</sup> and 50 mg kg<sup>–1</sup> day<sup>–1</sup> dosage could almost completely suppress the tumor progression (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B–D). It is worth mentioning that the PK profile obtained from rat may not be directly transformed into the mice due to the species difference.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>18</b>’s antitumor efficacy in MV4-11 xenograft model. Female nu/nu mice bearing established MV4-11 tumor xenografts were treated with <b>18</b> at 12.5, 25.0, 50.0 (mg/kg)/d or with vehicle. Daily oral administration was initiated when MV4-11 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained five animals. Data are the mean ± SEM. (A) Body weight and <b>(</b>B<b>)</b> tumor size measurements from MV4-11 xenograft mice after <b>18</b> administration. Initial body weight and tumor size were set as 100%. (C<b>)</b> Representative photographs of tumors in each group after 12.5, 25.0, or 50.0 (mg/kg)/d <b>18</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 22-day treatment period. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from irreversible BTK kinase inhibitor compound <b>1</b> (PCI-32765), we used a focused medicinal chemistry approach guided by structure based drug design to afford compound <b>18</b> (CHMFL-FLT3-122), which possessed highly potent inhibitory activities against FLT3-ITD positive AML cancer cell lines while showing good selectivity against the non-FLT3 dependent cancer cell lines. In addition, compound <b>18</b> has achieved better selectivity between the BTK kinase and FLT3 kinase compared to compound <b>1</b>. What is worth mentioning is that <b>18</b> has also achieved good selectivity over c-KIT kinase, which potentially will reduce the myelosuppression toxicity. Compound <b>18</b> exhibited suitable PK properties and strong in vivo antitumor activity. Currently compound <b>18</b> is under extensive preclinical evaluation, and we believe it will be a useful pharmacological candidate for further exploration of the therapeutic potential in the FLT3-ITD positive AML cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General Procedures</h3><div class="NLM_p">All solvents and reagents were used as obtained. <sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterium chloroform (CDCl<sub>3</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS experiments were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent Eclipse Plus C18 1.8 μm, 3.0 mm × 50 mm column. Purification of final compounds were performed with Isco CombiFlash Rf + system (silica flash column 4 g) using a gradient of 0–10% MeOH in DCM over 20 min at a flow rate of 18 mL/min. The purities of all compounds were above 95%.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0013.jpeg" id="GRAPHIC-d87e1537-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, NIS, 80 °C, 8 h; (b) DMF/H<sub>2</sub>O, Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, (4-phenoxyphenyl)boronic acid, 120 °C, 12 h; (c) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h; (d) 4 N HCl in EtOAc, rt, 1 h; (e) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypyrrolidine-1-carboxylate, 0 °C to rt, 12 h; (f) THF, triphenylphosphine, DIAD, <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h.</p></p></figure><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> 3-Iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S1</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">The mixture of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (10 g, 74 mmol) and <i>N</i>-iodosuccinimide (25 g, 111 mmol) in DMF (100 mL) was stirred at 80 °C for 8 h. The resulting mixture was allowed to cool to room temperature and then diluted with 300 mL of water. The precipitate was filtered and washed with 2 × 60 mL of saturated aqueous sodium sulfite, 2 × 100 mL of water, respectively, and dried under vacuum to yield <b>S1</b> as a yellow solid (14 g, 73%), which was used directly without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (br, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.13, 154.69, 153.35, 102.79, 91.06; LC/MS (ESI, <i>m</i>/<i>z</i>) 261.9591 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> 3-(4-Phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S2</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">To a mixture of <b>S1</b> (10 g, 38.3 mmol) and DMF/H<sub>2</sub>O (150 mL, v/v, 3/2) was added (4-phenoxyphenyl)boronic acid (9.8 g, 45.9 mmol), K<sub>3</sub>PO<sub>4</sub> (12.1 g, 57.4 mmol), and Pd(dppf)Cl<sub>2</sub> (1.4 g, 1.9 mmol). The reaction mixture was placed into an oil bath preheated to 120 °C, with stirring at this temperature for 12 h under argon. The resulting mixture was allowed to cool to room temperature, then diluted with 150 mL of water. The precipitate was filtered and dried under the vacuum. The crude product was recrystallized with MeOH to afford <b>S2</b> as an off-white color solid (7.2 g, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.57 (s, 1H), 8.23 (s, 1H), 7.68 (d, <i>J</i> = 7.8 Hz, 2H), 7.45 (t, <i>J</i> = 7.2 Hz, 2H), 7.26–7.08 (m, 5H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.59, 157.53, 156.77, 156.57, 155.26, 144.41, 130.54, 130.51, 128.93, 124.24, 119.44, 119.38, 97.46; LC/MS (ESI, <i>m</i>/<i>z</i>) 304.1217 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedure for the Preparation of Compounds <b>S3</b>, <b>S4</b>, and <b>S5</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (<i>R</i>)-3-(4-Phenoxyphenyl)-1-(piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S3</b>)</h4><div class="NLM_p last">To a mixture of triphenylphosphine (5.1 g, 19.8 mmol) in THF (300 mL) was added diisopropyl azodicarboxylate (3.9 mL, 19.8 mmol) at 0 °C. The reaction mixture was stirred at this temperature for 0.5 h under argon, then (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate (3.9 g, 19.8 mmol) was added. The reaction mixture was stirred at 0 °C for 0.5 h. After that, <b>S2</b> (3.0 g, 9.9 mmol) was added. The reaction mixture was allowed to warm to room temperature with stirring for 12 h. The resulting mixture was then concentrated to afford the crude product, which was purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to provide the desired Boc-protected monoamine as an off-white solid (3.3 g). Then to the solid in EtOAc (5 mL) was added 4 N HCl in EtOAc (15 mL). The reaction mixture was stirred at room temperature for 1 h. After complete conversion of the starting material, excess EtOAc was removed under vacuum. The residue was diluted in EtOAc and water. The water layer was basified with 2 N NaHCO<sub>3</sub> solution and extracted with EtOAc (2 × 100 mL). The organic layers were then washed with water followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide <b>S3</b> as an off-white solid (2.2 g, 84%) without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 7.67 (d, <i>J</i> = 7.9 Hz, 2H), 7.43 (t, <i>J</i> = 7.2 Hz, 2H), 7.15 (dt, <i>J</i> = 12.0, 7.8 Hz, 5H), 4.70 (t, <i>J</i> = 10.3 Hz, 1H), 3.09 (d, <i>J</i> = 9.0 Hz, 1H), 3.19 (s, 1H), 2.95 (dd, <i>J</i> = 24.7, 12.8 Hz, 2H), 2.47 (d, <i>J</i> = 11.5 Hz, 1H), 2.22–2.07 (m, 1H), 2.01 (d, <i>J</i> = 17.3 Hz, 1H), 1.75 (d, <i>J</i> = 12.3 Hz, 1H), 1.56 (d, <i>J</i> = 12.2 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.64, 157.52, 156.80, 155.93, 154.24, 143.26, 130.57, 130.52, 128.61, 124.22, 119.43, 97.83, 54.40, 51.29, 45.91, 30.75, 26.47; LC/MS (ESI, <i>m</i>/<i>z</i>) 387.1904 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> (<i>R</i>)-3-(4-Phenoxyphenyl)-1-(pyrrolidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S4</b>)</h4><div class="NLM_p last">Overall yield from <b>S2</b> = 53%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.68 (d, <i>J</i> = 8.2 Hz, 2H), 7.42 (t, <i>J</i> = 7.5 Hz, 2H), 7.15 (dt, <i>J</i> = 12.5, 7.9 Hz, 5H), 5.32 (s, 1H), 3.59 (s, 1H), 3.29–3.01 (m, 3H), 2.93 (s, 1H), 2.28–2.06 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.64, 157.55, 156.80, 156.01, 154.38, 143.44, 130.56, 128.59, 124.21, 119.41, 98.00, 57.27, 53.26, 46.94, 32.96; LC/MS (ESI, <i>m</i>/<i>z</i>) 373.1783 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 3-(4-Phenoxyphenyl)-1-(piperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S5</b>)</h4><div class="NLM_p">Overall yield from <b>S2</b> = 53%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (s, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.43 (t, <i>J</i> = 7.3 Hz, 2H), 7.25–7.07 (m, 5H), 4.74 (t, <i>J</i> = 11.3 Hz, 1H), 3.07 (d, <i>J</i> = 11.6 Hz, 2H), 2.63 (t, <i>J</i> = 11.7 Hz, 2H), 2.05 (d, <i>J</i> = 8.4 Hz, 3H), 1.83 (d, <i>J</i> = 10.6 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.64, 157.52, 156.79, 155.87, 153.90, 143.21, 130.57, 130.49, 128.68, 124.23, 119.45, 119.41, 97.88, 54.92, 45.89, 33.05; LC/MS (ESI, <i>m</i>/<i>z</i>) 387.1911 [M + H]<sup>+</sup>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0014.jpeg" id="GRAPHIC-d87e1932-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) bis(pinacolato)diboron, 1,4-dioxane, KOAc, Pd(dppf)Cl<sub>2,</sub> 100 °C, 12 h; (b) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h; (c) 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 100 °C, 12 h; (d) 4 N HCl in EtOAc, rt, 1 h.</p></p></figure></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (<i>E</i>)-4,4,5,5-Tetramethyl-2-(4-styrylphenyl)-1,3,2-dioxaborolane (<b>S6</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-1-bromo-4-styrylbenzene (1.0 g, 3.8 mmol) in 1,4-dioxane (10 mL) were added bis(pinacolato)diboron (1.1 g, 4.2 mmol), KOAc (0.56 g, 5.7 mmol), and Pd(dppf)Cl<sub>2</sub> (0.14 g, 0.19 mmol) at room temperature. The reaction mixture was stirred overnight at 100 °C under argon protection. The resulting mixture was concentrated and purified by silica gel column chromatography (dichloromethane) to afford <b>S6</b> as a light yellow solid (1.0 g, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.85 (d, <i>J</i> = 7.6 Hz, 2H), 7.56 (d, <i>J</i> = 7.5 Hz, 4H), 7.51–7.36 (m, 2H), 7.36–7.26 (m, 1H), 7.19 (q, <i>J</i> = 16.3 Hz, 2H), 1.47 (d, <i>J</i> = 62.0 Hz, 12H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 140.09, 137.23, 135.25, 129.72, 128.71, 127.87, 126.69, 125.88, 83.82, 83.55, 25.03.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (<i>R</i>)-<i>tert</i>-Butyl 3-(4-Amino-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>S7</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p last">To a mixture of 3-iodo-1<i>H</i>-pyrazolo-[3,4-<i>d</i>]pyrimidin-4-amine (1.0 g, 3.3 mmol) in THF (150 mL) was added triphenylphosphine (1.7 g, 6.6 mmol), diisopropyldiazene 1,2-dicarboxylate (1.3 mL, 6.6 mmol), and (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate (1.3 g, 6.6 mmol) at room temperature. The reaction mixture was stirred for 16 h and was judged complete by LC/MS. The resulting mixture was concentrated to give the crude product, which was purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to provide <b>S7</b> as a white solid (1.0 g, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 6.41 (s, 2H), 4.76 (m, 1H), 4.12 (d, <i>J</i> = 6.7 Hz, 2H), 3.36 (s, 1H), 2.84 (t, <i>J</i> = 11.5 Hz, 1H), 2.30–2.06 (m, 2H), 1.88 (d, <i>J</i> = 11.4 Hz, 1H), 1.66 (d, <i>J</i> = 11.7 Hz, 1H), 1.45 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 157.77, 155.73, 154.58, 153.47, 103.92, 86.34, 79.96, 53.45, 30.19, 28.39; LC/MS (ESI, <i>m</i>/<i>z</i>) 445.0993 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>R</i>,<i>E</i>)-<i>tert</i>-Butyl 3-(4-Amino-3-(4-styrylphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidine-1-carboxylate (<b>S8</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p last">To a solution of <b>S6</b> (0.07 g, 0.2 mmol), <b>S7</b> (0.1 g, 0.2 mmol), K<sub>2</sub>CO<sub>3</sub> (0.06 g, 0.4 mmol) in 1,4-dioxane/H<sub>2</sub>O (12 mL, v/v = 5/1) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (0.013g, 0.01 mmol) at room temperature. The reaction mixture was stirred overnight at 100 °C under argon protection. The resulting mixture was concentrated and purified by silica gel column chromatography (eluting with 0–2% MeOH in DCM) to afford <b>S8</b> as a white solid (0.1 g, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 7.69 (s, 4H), 7.55 (d, <i>J</i> = 7.3 Hz, 2H), 7.39 (t, <i>J</i> = 7.1 Hz, 2H), 7.30 (d, <i>J</i> = 7.7 Hz, 1H), 7.19 (d, <i>J</i> = 5.7 Hz, 2H), 4.86 (s, 1H), 4.12 (d, <i>J</i> = 7.0 Hz, 2H), 2.87 (t, <i>J</i> = 12.2 Hz, 1H), 2.36–2.14 (m, 2H), 2.07 (d, <i>J</i> = 20.1 Hz, 1H), 1.91 (s, 1H), 1.71 (d, <i>J</i> = 11.9 Hz, 1H), 1.24 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.13, 155.22, 154.69, 154.03, 144.15, 138.12, 136.91, 132.12, 129.93, 128.75, 127.99, 127.63, 127.33, 126.64, 98.51, 79.92, 74.99, 52.93, 30.11, 28.39, 24.85; LC/MS (ESI, <i>m</i>/<i>z</i>) 497.2689 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>E</i>)-1-(Piperidin-3-yl)-3-(4-styrylphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>S9</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p">To a solution of <b>S8</b> (0.1 g, 0.2 mmol) in EtOAc (2 mL) was added 4 N HCl in EtOAc (4 mL). The reaction mixture was stirred at room temperature for 1 h. After complete conversion of the starting material, excess EtOAc was removed under vacuum. To the residue were added EtOAc and water. The water layer was basified with 2 N NaHCO<sub>3</sub> solution and extracted with EtOAc (2 × 50 mL). The organic layers were then washed with water followed by brine. The organic layers were dried over sodium sulfate, filtered, and concentrated to provide <b>S9</b> as an off-white solid (65 mg, 82%) without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (s, 1H), 7.70 (s, 4H), 7.57 (d, <i>J</i> = 7.0 Hz, 2H), 7.40 (d, <i>J</i> = 7.3 Hz, 2H), 7.36–7.26 (m, 1H), 7.21 (s, 2H), 5.94 (s, 2H), 4.88 (s, 1H), 3.34 (s, 1H), 3.10 (d, <i>J</i> = 11.3 Hz, 1H), 2.81 (d, <i>J</i> = 10.5 Hz, 1H), 2.34 (d, <i>J</i> = 9.4 Hz, 1H), 2.21 (m, 1H), 2.06 (s, 1H), 1.91 (m, 1H), 1.72 (m, 1H), 1.28 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.19, 155.42, 153.96, 144.16, 138.09, 136.93, 132.26, 129.91, 128.78, 128.01, 127.66, 127.35, 126.66, 98.47, 53.92, 50.14, 45.41, 30.14, 25.53; LC/MS (ESI, <i>m</i>/<i>z</i>) 397.2135 [M + H]<sup>+</sup>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0015.jpeg" id="GRAPHIC-d87e2262-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: RC(O)Cl or RSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: RCOOH, HATU, DIEA, DMF, 30 min. Method C: (i) <i>N</i>-Boc-AA-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0016.jpeg" id="GRAPHIC-d87e2281-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: MeSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: 2-(dimethylamino)acetic acid, HATU, DIEA, DMF, 30 min. Method C: (i) <i>N</i>-Boc-AA-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0017.jpeg" id="GRAPHIC-d87e2300-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: MeSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: 2-(dimethylamino)acetic acid, HATU, DIEA, DMF, 30 min; Method C: (i) <i>N</i>-Boc-(D)Leu-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Method A: General Procedure for the Preparation of Compounds <b>1</b>–<b>9</b>, <b>13</b>–<b>15</b>, <b>27</b>, and <b>32</b> (<a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>)</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>1</b>, PCI-32765)</h4><div class="NLM_p last">To a solution of <b>S3</b> (20 mg, 0.05 mmol) in dichloromethane (3 mL) were added DIEA (7.4 mg, 0.05 mmol) and acryloyl chloride (5.1 mg, 0.05 mmol) at 0 °C. The resulting mixture was stirred for 3 min. Then it was quenched by MeOH (1 mL), concentrated, and purified with CombiFlash system (0–10% MeOH in DCM) to afford the title compound <b>1</b> (18 mg, 81%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.67 (d, <i>J</i> = 6.9 Hz, 2H), 7.45 (t, <i>J</i> = 7.3 Hz, 2H), 7.27–7.08 (m, 5H), 6.97–6.81 (m, 0.5H), 6.81–6.64 (m, 0.5H), 6.11 (dd, <i>J</i> = 26.1, 16.8 Hz, 1H), 5.66 (dd, <i>J</i> = 47.4, 9.8 Hz, 1H), 4.72 (s, 1H), 4.57 (d, <i>J</i> = 10.8 Hz, 0.5H), 4.22 (s, 1H), 4.09 (d, <i>J</i> = 13.2 Hz, 0.5H), 3.73 (d, <i>J</i> = 10.9 Hz, 0.5H), 3.21 (d, <i>J</i> = 9.7 Hz, 1H), 3.02 (s, 0.5H), 2.28 (d, <i>J</i> = 11.2 Hz, 1H), 2.14 (s, 1H), 1.94 (d, <i>J</i> = 12.4 Hz, 1H), 1.59 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.04, 158.68, 157.61, 156.79, 156.14, 154.46, 143.80, 130.58, 128.82, 128.43, 127.91, 127.69, 124.24, 119.44, 97.90, 53.23, 52.54, 49.78, 46.23, 30.12, 25.41; LC/MS (ESI, <i>m</i>/<i>z</i>) 441.2015 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>R</i>,<i>E</i>)-1-(3-(4-Amino-3-(4-styrylphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (<b>2</b>)</h4><div class="NLM_p last">Yield = 80%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.79 (d, <i>J</i> = 7.2 Hz, 2H), 7.68 (dd, <i>J</i> = 16.2, 7.3 Hz, 4H), 7.40 (dd, <i>J</i> = 15.3, 6.8 Hz, 4H), 7.31 (d, <i>J</i> = 6.8 Hz, 1H), 6.85 (dd, <i>J</i> = 42.3, 27.4 Hz, 1H), 6.22–6.02 (m, 1H), 5.71 (dd, <i>J</i> = 33.8, 24.5 Hz, 1H), 4.74 (s, 1H), 4.57 (s, 0.5H), 4.24 (s, 1H), 4.11 (s, 0.5H), 3.74 (s, 0.5H), 3.31–3.14 (m, 1H), 3.04 (s, 0.5H), 2.30 (d, <i>J</i> = 10.9 Hz, 1H), 2.16 (s, 1H), 1.95 (d, <i>J</i> = 11.6 Hz, 1H), 1.60 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.06, 158.71, 156.15, 154.58, 144.04, 137.77, 137.40, 132.41, 129.68, 129.22, 129.06, 128.83, 128.31, 127.61, 127.07, 97.96, 55.38, 49.78, 46.23, 30.11, 25.40; LC/MS (ESI, <i>m</i>/<i>z</i>) 451.2244 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one (<b>3</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 9.5 Hz, 1H), 7.67 (d, <i>J</i> = 7.4 Hz, 2H), 7.44 (t, <i>J</i> = 7.1 Hz, 2H), 7.25–7.08 (m, 5H), 4.75 (s, 0.5H), 4.64 (s, 0.5H), 4.55 (d, <i>J</i> = 11.4 Hz, 0.5H), 4.25 (d, <i>J</i> = 12.4 Hz, 0.5H), 4.03 (d, <i>J</i> = 11.6 Hz, 0.5H), 3.89 (d, <i>J</i> = 12.1 Hz, 0.5H), 3.66–3.49 (m, 0.5H), 3.11 (d, <i>J</i> = 8.6 Hz, 1H), 2.83 (d, <i>J</i> = 10.6 Hz, 0.5H), 2.35 (d, <i>J</i> = 26.7 Hz, 1H), 2.33–2.18 (m, 2H), 2.12 (s, 1H), 1.89 (s, 1H), 1.72–1.45 (m, 1H), 1.00 (dd, <i>J</i> = 15.6, 7.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.97, 158.68, 157.61, 156.78, 156.15, 156.15, 154.51, 143.74, 130.56, 128.44, 124.23, 119.43, 97.96, 52.61, 49.62, 45.85, 30.12, 26.10, 23.98, 9.89; LC/MS (ESI, <i>m</i>/<i>z</i>) 443.2293.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)ethanone (<b>4</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 10.3 Hz, 1H), 7.67 (d, <i>J</i> = 7.5 Hz, 2H), 7.61–7.39 (m, 2H), 7.28–7.07 (m, 5H), 4.77 (s, 0.5H), 4.63 (s, 05H), 4.52 (d, <i>J</i> = 12.5 Hz, 0.5H), 4.19 (d, <i>J</i> = 11.8 Hz, 0.5H), 4.00 (d, <i>J</i> = 12.9 Hz, 0.5H), 3.85 (d, <i>J</i> = 12.6 Hz, 0.5H), 3.23–3.01 (m, 1H), 2.85 (t, <i>J</i> = 11.6 Hz, 1H), 2.23 (d, <i>J</i> = 11.5 Hz, 1H), 2.09 (d, <i>J</i> = 19.9 Hz, 3H), 2.00–1.83 (m, 2H), 1.75–1.44 (m, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.83, 158.68, 157.60, 156.79, 156.16, 154.46, 143.71, 130.58, 128.43, 124.25, 119.44, 97.90, 53.09, 50.45, 45.60, 29.79, 23.87, 21.74; LC/MS (ESI, <i>m</i>/<i>z</i>) 429.2036 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)butan-1-one (<b>5</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 9.3 Hz, 1H), 7.67 (d, <i>J</i> = 7.3 Hz, 2H), 7.44 (t, <i>J</i> = 7.1 Hz, 2H), 7.26–7.07 (m, 5H), 4.74 (s, 0.5H), 4.63 (s, 0.5H), 4.54 (d, <i>J</i> = 11.0 Hz, 0.5H), 4.22 (d, <i>J</i> = 12.1 Hz, 0.5H), 4.04 (d, <i>J</i> = 11.6 Hz, 0.5H), 3.90 (d, <i>J</i> = 13.2 Hz, 0.5H), 3.60 (t, <i>J</i> = 11.2 Hz, 0.5H), 3.11 (s, 1H), 2.86 (t, <i>J</i> = 11.1 Hz, 0.5H), 2.34 (d, <i>J</i> = 6.2 Hz, 1H), 2.26 (d, <i>J</i> = 5.9 Hz, 1H), 2.14 (d, <i>J</i> = 18.7 Hz, 1H), 1.90 (s, 1H), 1.54 (dd, <i>J</i> = 14.0, 7.0 Hz, 3H), 1.35–1.19 (m, 1H), 0.87 (dt, <i>J</i> = 27.4, 6.7 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.18, 158.62, 157.61, 156.78, 156.08, 154.37, 143.75, 130.58, 128.41, 124.24, 119.43, 97.95, 52.63, 49.72, 45.77, 34.77, 30.10, 25.20, 18.70, 14.27; LC/MS (ESI, <i>m</i>/<i>z</i>) 457.2321 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one (<b>6</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.68 (d, <i>J</i> = 8.2 Hz, 2H), 7.44 (t, <i>J</i> = 7.5 Hz, 2H), 7.17 (dt, <i>J</i> = 12.8, 7.9 Hz, 5H), 4.70 (s, 1H), 4.45 (d, <i>J</i> = 12.0 Hz, 1H), 4.29 (d, <i>J</i> = 12.5 Hz, 1H), 3.27 (t, <i>J</i> = 11.6 Hz, 1H), 2.96 (d, <i>J</i> = 11.4 Hz, 1H), 2.38–2.22 (m, 1H), 2.13 (s, 1H), 1.92 (d, <i>J</i> = 12.7 Hz, 1H), 1.59 (d, <i>J</i> = 12.4 Hz, 1H), 1.29–1.16 (m, 9H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.61, 158.63, 157.60, 156.78, 156.05, 154.41, 143.77, 130.59, 130.56, 128.41), 124.25, 119.44, 97.89, 52.96, 49.15, 45.43, 38.74, 30.02, 28.58, 24.89; LC/MS (ESI, <i>m</i>/<i>z</i>) 471.2512 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2,2-dimethylbutan-1-one (<b>7</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.68 (d, <i>J</i> = 7.8 Hz, 2H), 7.45 (t, <i>J</i> = 7.1 Hz, 2H), 7.25–7.07 (m, 5H), 4.68 (s, 1H), 4.47 (d, <i>J</i> = 12.2 Hz, 1H), 4.31 (d, <i>J</i> = 12.0 Hz, 1H), 2.97 (s, 1H), 2.29 (d, <i>J</i> = 11.6 Hz, 1H), 2.14 (s, 1H), 1.97 (dd, <i>J</i> = 33.6, 10.6 Hz, 2H), 1.61 (s, 3H), 1.18 (d, <i>J</i> = 10.0 Hz, 6H), 0.83 (t, <i>J</i> = 6.9 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.72, 158.67, 157.60, 156.78, 156.11, 154.44, 143.74, 130.57, 130.54, 128.43, 124.24, 119.43, 97.92, 53.02, 49.08, 45.27, 42.90, 33.06, 30.00, 26.74, 24.94, 9.91; LC/MS (ESI, <i>m</i>/<i>z</i>) 485.2644 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-3,3-dimethylbutan-1-one (<b>8</b>)</h4><div class="NLM_p last">Yield = 82%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.68 (s, 2H), 7.45 (s, 2H), 7.14 (dd, <i>J</i> = 22.4, 12.5 Hz, 5H), 4.74 (s, 0.5H), 4.60 (s, 0.5H), 4.32 (s, 0.5H), 4.15 (d, <i>J</i> = 12.1 Hz, 0.5H), 4.00 (d, <i>J</i> = 13.1 Hz,0.5H), 3.64 (d, <i>J</i> = 10.0 Hz, 0.5H), 3.13 (d, <i>J</i> = 12.6 Hz, 1H), 2.83 (s, 1H), 2.27 (dd, <i>J</i> = 22.0, 9.2 Hz, 2H), 2.13 (s, 1H), 1.92 (s, 1H), 1.25 (s, 2H), 0.99 (d, <i>J</i> = 18.5 Hz, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.09, 158.67, 157.59, 156.80, 156.10, 154.38, 143.72, 130.58, 128.45, 124.24, 119.46, 119.42, 97.98, 52.71, 50.45, 45.60, 44.29, 41.39, 31.37, 30.20, 25.16; LC/MS (ESI, <i>m</i>/<i>z</i>) 485.2643 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)(cyclopropyl)methanone (<b>9</b>)</h4><div class="NLM_p last">Yield = 82%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.68 (d, <i>J</i> = 8.1 Hz, 2H), 7.44 (t, <i>J</i> = 7.4 Hz, 2H), 7.17 (dt, <i>J</i> = 12.9, 7.8 Hz, 5H), 4.79 (s, 0.5H), 4.65 (s, 0.5H), 4.50 (s, 0.5H), 4.37 (d, <i>J</i> = 11.5 Hz, 0.5H), 4.26 (s, 0.5H), 4.17 (s, 0.5H), 3.79 (s, 0.5H), 3.29–3.08 (m, 0.5H), 2.96 (s, 1H), 2.28 (d, <i>J</i> = 10.2 Hz, 1H), 2.15 (s, 1H), 2.08–1.81 (m, 1H), 1.61 (d, <i>J</i> = 47.1 Hz, 1H), 1.28 (dt, <i>J</i> = 19.1, 9.6 Hz, 1H), 0.63 (d, <i>J</i> = 95.8 Hz, 4H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.70, 158.64, 157.59, 156.79, 156.09, 154.39, 143.72, 130.59, 130.54, 128.43, 124.24, 119.46, 119.43, 97.86, 53.92, 49.63, 46.43, 30.19, 25.41, 18.50, 10.93, 7.32; LC/MS (ESI, <i>m</i>/<i>z</i>) 455.2236 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-1-(1-(Methylsulfonyl)piperidin-3-yl)-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>13</b>)</h4><div class="NLM_p last">Yield = 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.45 (t, <i>J</i> = 7.5 Hz, 2H), 7.17 (td, <i>J</i> = 14.2, 7.7 Hz, 5H), 4.84 (s, 1H), 3.77 (d, <i>J</i> = 9.0 Hz, 1H), 3.62 (d, <i>J</i> = 11.8 Hz, 1H), 3.34 (s, 3H), 3.17 (t, <i>J</i> = 10.9 Hz, 1H), 2.83 (t, <i>J</i> = 11.6 Hz, 1H), 2.28–2.08 (m, 2H), 1.99 (d, <i>J</i> = 13.3 Hz, 1H), 1.75 (d, <i>J</i> = 12.4 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.55, 157.72, 156.62, 156.21, 154.33, 144.01, 130.60, 128.11, 124.38, 119.43, 97.91, 52.94, 49.65, 45.72, 35.09, 29.00, 24.20; LC/MS (ESI, <i>m</i>/<i>z</i>) 304.1217 [M + H]<sup>+</sup> TOF LC/MS: (ESI) <i>m</i>/<i>z</i>: 465.1754 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-1-(1-(Ethylsulfonyl)piperidin-3-yl)-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>14</b>)</h4><div class="NLM_p last">Yield = 83%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.68 (d, <i>J</i> = 7.8 Hz, 2H), 7.44 (d, <i>J</i> = 7.3 Hz, 2H), 7.17 (td, <i>J</i> = 14.2, 7.8 Hz, 5H), 4.81 (s, 1H), 3.81 (d, <i>J</i> = 11.4 Hz, 1H), 3.66 (d, <i>J</i> = 11.1 Hz, 1H), 3.28 (d, <i>J</i> = 10.6 Hz, 1H), 3.11 (d, <i>J</i> = 7.1 Hz, 2H), 2.94 (t, <i>J</i> = 11.7 Hz, 1H), 2.31–2.06 (m, 2H), 1.97 (d, <i>J</i> = 13.4 Hz, 1H), 1.72 (d, <i>J</i> = 11.0 Hz, 1H), 1.21 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.68, 157.63, 156.79, 156.23, 154.53, 143.89, 130.58, 130.56, 128.35, 124.24, 119.46, 119.42, 97.94, 53.10, 49.52, 45.62, 43.75, 29.24, 24.75, 8.02; LC/MS (ESI, <i>m</i>/<i>z</i>) 479.1836 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-3-(4-Phenoxyphenyl)-1-(1-(propylsulfonyl)piperidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>15</b>)</h4><div class="NLM_p last">Yield = 83%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.68 (d, <i>J</i> = 7.9 Hz, 2H), 7.45 (t, <i>J</i> = 7.2 Hz, 2H), 7.17 (td, <i>J</i> = 14.3, 7.7 Hz, 5H), 4.81 (s, 1H), 3.79 (d, <i>J</i> = 9.8 Hz, 1H), 3.64 (d, <i>J</i> = 11.3 Hz, 1H), 3.27 (t, <i>J</i> = 11.0 Hz, 1H), 3.15–2.99 (m, 2H), 2.91 (t, <i>J</i> = 11.8 Hz, 1H), 2.31–2.06 (m, 2H), 1.97 (d, <i>J</i> = 13.2 Hz, 1H), 1.67 (dd, <i>J</i> = 14.7, 7.4 Hz, 3H), 0.96 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.68, 157.62, 156.79, 156.22, 154.53, 143.88, 130.58, 130.55, 128.36, 124.24, 119.46, 119.41, 97.93, 53.07, 50.48, 49.51, 45.57, 29.20, 24.66, 16.91, 13.22; LC/MS (ESI, <i>m</i>/<i>z</i>) 493.2013 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(1-(Methylsulfonyl)piperidin-4-yl)-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>27</b>)</h4><div class="NLM_p last">Yield = 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.45 (t, <i>J</i> = 7.4 Hz, 2H), 7.28–7.07 (m, 5H), 4.86 (s, 1H), 3.73 (d, <i>J</i> = 11.6 Hz, 2H), 3.03 (t, <i>J</i> = 11.4 Hz, 2H), 2.95 (s, 3H), 2.22 (d, <i>J</i> = 9.7 Hz, 2H), 2.07 (d, <i>J</i> = 10.7 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.67, 157.63, 156.73, 156.00, 154.25, 143.58, 130.56, 130.51, 128.45, 124.25, 119.48, 119.40, 98.04, 64.92, 53.30, 45.15, 43.42, 35.27, 30.94; LC/MS (ESI, <i>m</i>/<i>z</i>) 465.1747 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-1-(1-(Methylsulfonyl)pyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>32</b>)</h4><div class="NLM_p last">Yield = 89%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.69 (d, <i>J</i> = 8.6 Hz, 2H), 7.45 (t, <i>J</i> = 7.8 Hz, 2H), 7.28–7.08 (m, 5H), 5.56 (s, 1H), 3.97–3.79 (m, 1H), 3.74–3.43 (m, 3H), 2.97 (s, 3H), 2.46 (d, <i>J</i> = 7.8 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.69, 157.72, 156.70, 156.25, 154.65, 144.02, 130.58, 130.55, 128.27, 124.29, 119.52, 119.41, 98.11, 55.55, 52.15, 47.31, 34.36, 31.56; LC/MS (ESI, <i>m</i>/<i>z</i>) 451.1563 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Method B: General Procedure for the Preparation of Compounds <b>10</b>–<b>12</b>, <b>18</b>, <b>25</b>, <b>26</b> and <b>30</b> (<a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>)</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-cyclopropylethanone (<b>10</b>)</h4><div class="NLM_p last">To a solution of <b>S3</b> (30 mg, 0.07 mmol) in DMF (2 mL) were added 2-cyclopropylacetic acid (7.7 mg, 0.07 mmol), HATU (29.5 mg, 0.07 mmol), and DIEA (7.4 mg, 0.05 mmol). The reaction mixture was stirred for 30 min. Then it was diluted with EtOAc (60 mL), washed with water (20 mL × 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified with CombiFlash system (0–10% MeOH in DCM) to afford the title compound <b>10</b> (37 mg, 80%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.67 (d, <i>J</i> = 4.7 Hz, 2H), 7.44 (t, <i>J</i> = 7.3 Hz, 2H), 7.25–7.09 (m, 5H), 4.62 (dd, <i>J</i> = 56.2, 27.8 Hz, 1H), 4.24 (d, <i>J</i> = 12.5 Hz, 0.5H), 4.02 (d, <i>J</i> = 10.2 Hz, 0.5H), 3.87 (d, <i>J</i> = 12.6 Hz, 0.5H), 3.69–3.50 (m, 0.5H), 3.11 (dd, <i>J</i> = 21.0, 10.5 Hz, 1H), 2.94–2.79 (m, 1H), 2.39–2.19 (m,2H), 2.12 (d, <i>J</i> = 7.6 Hz, 1H), 1.91 (d, <i>J</i> = 12.0 Hz, 1H), 1.70–1.45 (m, 1H), 1.20 (dd, <i>J</i> = 17.2, 10.3 Hz, 1H), 0.97 (d, <i>J</i> = 5.7 Hz, 1H), 0.44 (dd, <i>J</i> = 16.8, 7.4 Hz, 2H), 0.11 (d, <i>J</i> = 23.4 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.99, 158.66, 157.60, 156.77, 156.14, 154.50, 143.75, 130.59, 130.54, 128.41, 124.25, 119.46, 119.42, 97.84, 52.62, 49.85, 45.78, 38.01, 30.10, 25.25, 7.75, 4.84; LC/MS (ESI, <i>m</i>/<i>z</i>) 469.2331 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>R</i>)-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)(1-methylpiperidin-4-yl)methanone (<b>11</b>)</h4><div class="NLM_p last">Yield = 71%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 7.6 Hz, 1H), 7.68 (d, <i>J</i> = 7.0 Hz, 2H), 7.44 (t, <i>J</i> = 7.2 Hz, 2H), 7.17 (dt, <i>J</i> = 12.1, 7.9 Hz, 5H), 4.87 (s, 0.5H), 4.64 (s, 0.5H), 4.42 (d, <i>J</i> = 10.3 Hz, 0.5H), 4.29 (d, <i>J</i> = 10.1 Hz, 1H), 4.02 (d, <i>J</i> = 12.1 Hz, 0.5H), 3.67–3.52 (m, 1H), 3.42 (s, 3H), 3.18 (ddd, <i>J</i> = 39.9, 25.2, 12.9 Hz, 2H), 2.76 (dd, <i>J</i> = 26.0, 12.2 Hz, 1H), 2.36 (s, 4H), 2.20 (d, <i>J</i> = 13.4 Hz, 4H), 2.10 (s, 1H), 2.00–1.81 (m, 1H), 1.51 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.28, 158.69, 157.59, 156.79, 156.10, 154.34, 144.03, 130.59, 130.52, 128.43, 124.25, 119.42, 54.90, 53.49, 52.61, 49.49, 46.22, 37.26, 30.11, 28.76), 25.50; LC/MS (ESI, <i>m</i>/<i>z</i>) 512.2815 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-(4-methylpiperazin-1-yl)ethanone (<b>12</b>)</h4><div class="NLM_p last">Yield = 75%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 7.6 Hz, 1H), 7.68 (d, <i>J</i> = 7.0 Hz, 2H), 7.44 (t, <i>J</i> = 7.2 Hz, 2H), 7.17 (dt, <i>J</i> = 12.1, 7.9 Hz, 5H), 4.87 (s, 0.5H), 4.64 (s, 0.5H), 4.42 (d, <i>J</i> = 10.3 Hz, 0.5H), 4.29 (d, <i>J</i> = 10.1 Hz, 1H), 4.02 (d, <i>J</i> = 12.1 Hz, 0.5H), 3.67–3.54 (m, 1H), 3.42 (s, 3H), 3.18 (ddd, <i>J</i> = 39.9, 25.2, 12.9 Hz, 2H), 2.76 (dd, <i>J</i> = 26.0, 12.2 Hz, 1H), 2.36 (s, 5H), 2.22 (s, 3H), 2.18 (s, 1H), 2.10 (s, 1H), 1.99–1.81 (m, 0.5H), 1.69 (s, 0.5H), 1.51 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.98, 158.67, 157.61, 156.77, 156.09, 154.43, 143.70, 130.59, 128.41, 124.27, 119.44, 97.86, 61.70, 55.06, 54.49, 53.41, 52.70, 50.16, 45.85, 30.35, 24.49; LC/MS (ESI, <i>m</i>/<i>z</i>) 527.2876 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (<b>18</b>)</h4><div class="NLM_p last">Yield = 81%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (d, <i>J</i> = 7.7 Hz, 2H), 7.44 (t, <i>J</i> = 7.1 Hz, 2H), 7.28–7.08 (m, 5H), 4.82 (s, 0.5H), 4.65 (s, 0.5H), 4.49 (d, <i>J</i> = 10.9 Hz, 0.5H), 4.19 (d, <i>J</i> = 11.1 Hz, 1H), 4.02 (d, <i>J</i> = 11.9 Hz, 0.5H), 3.70–3.56 (m, 1H), 3.17 (d, <i>J</i> = 11.5 Hz, 2H), 2.89 (t, <i>J</i> = 10.6 Hz, 1H), 2.26 (s, 4H), 2.13 (d, <i>J</i> = 27.5 Hz, 4H), 1.91 (d, <i>J</i> = 9.6 Hz, 1H), 1.61 (d, <i>J</i> = 52.6 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.08, 158.68, 157.61, 156.77, 156.11, 154.35, 144.15, 130.56, 128.43, 124.23, 119.43, 97.86, 62.14, 53.20, 50.24, 45.87, 45.42, 30.05, 24.09; LC/MS (ESI, <i>m</i>/<i>z</i>) 472.2451 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (<b>25</b>)</h4><div class="NLM_p last">Yield = 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (s, 1H), 7.68 (s, 2H), 7.45 (s, 2H), 7.17 (d, <i>J</i> = 8.4 Hz, 5H), 4.83 (s, 0.5H), 4.65 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (s, 1H), 4.05 (s, 0.5H), 3.63 (s, 0.5H), 3.17 (s, 2H), 2.90 (s, 1H), 2.26 (s, 4H), 2.16 (s, 4H), 1.91 (s, 1H), 1.68 (s, 0.5H), 1.55 (s, 0.5H), 1.25 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.11, 158.67, 157.60, 156.78, 156.45, 154.47, 143.69, 130.58, 128.42, 124.25, 119.44, 97.92, 62.13, 52.64, 49.75, 45.48, 30.02, 25.13, 24.07; LC/MS (ESI, <i>m</i>/<i>z</i>) 472.2462 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(4-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (<b>26</b>)</h4><div class="NLM_p last">Yield = 73%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 7.66 (d, <i>J</i> = 7.9 Hz, 2H), 7.45 (t, <i>J</i> = 7.2 Hz, 2H), 7.28–7.06 (m, 5H), 5.00 (s, 1H), 4.50 (d, <i>J</i> = 12.8 Hz, 1H), 4.15 (d, <i>J</i> = 12.3 Hz, 1H), 3.33–3.22 (m, 3H), 2.85 (s, 1H), 2.29 (s, 6H), 2.15 (d, <i>J</i> = 12.2 Hz, 1H), 1.97 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.24, 158.66, 157.58, 156.77, 155.99, 154.11, 143.49, 130.559, 130.51, 128.51, 124.26, 119.45, 97.94, 62.52, 53.85, 45.62, 32.11; LC/MS (ESI, <i>m</i>/<i>z</i>) 472.2450 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)pyrrolidin-1-yl)-2-(dimethylamino)ethanone (<b>30</b>)</h4><div class="NLM_p last">Yield = 72%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.67 (d, <i>J</i> = 8.2 Hz, 2H), 7.45 (t, <i>J</i> = 7.4 Hz, 2H), 7.29–7.08 (m, 5H), 5.54 (d, <i>J</i> = 28.8 Hz, 1H), 4.13–3.53 (m, 6H), 2.70 (d, <i>J</i> = 16.0 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.41, 158.66, 157.65, 156.77, 156.20, 154.68, 154.63, 143.84, 130.60, 130.51, 128.38, 124.27, 119.46, 98.06, 62.67, 55.81, 50.47, 45.66, 31.81, 29.51; LC/MS (ESI, <i>m</i>/<i>z</i>) 458.2290 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Method C: General Procedure for the Preparation of Compounds <b>16</b>, <b>17</b>, <b>19</b>–<b>24</b>, <b>28</b>, <b>29</b>, and <b>31</b> (<a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>)</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>R</i>)-2-Amino-1-(3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)ethanone Hydrochloride (<b>16</b>)</h4><div class="NLM_p last">To a solution of <b>S3</b> (40 mg, 0.13 mmol) in DMF (2 mL) were added 2-((<i>tert</i>-butoxycarbonyl)amino)acetic acid (23 mg, 0.13 mmol), HATU (50.2 mg, 0.13 mmol), and DIEA (17.1 mg, 0.13 mmol). The resulting mixture was stirred for 30 min. Then it was diluted with EtOAc (80 mL), washed with water (20 mL × 3) and brine (30 mL). The organic layers were dried over anhydrous sodium sulfate, concentrated, and purified with CombiFlash system (0–10% MeOH in DCM) to afford the Boc-protected monoamine (50 mg) as a white solid. Then the solid was dissolved with 4 N HCl in EtOAc (5 mL). The resulting mixture was stirred at room temperature for 1 h. Excess EtOAc was removed under vacuum to afford the final product <b>16</b> (35 mg, 37%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 7.68 (s, 2H), 7.45 (s, 2H), 7.17 (d, <i>J</i> = 9.1 Hz, 5H), 4.81 (s, 0.5H), 4.67 (m, 0.5H), 4.55 (m, 0.5H), 4.27 (m, 0.5H), 3.95 (d, <i>J</i> = 12.4 Hz, 1H), 3.72 (d, <i>J</i> = 16.0 Hz, 3H), 3.18 (s, 2H), 2.94 (m, 1H), 2.26 (m, 1H), 2.14 (m, 1H), 1.90 (m, 1H), 1.64 (d, <i>J</i> = 56.5 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.39, 158.26, 156.52, 153.90, 152.20, 148.77, 146.39, 130.66, 126.63, 124.47, 119.58, 97.33, 53.15, 48.23, 46.02, 44.65, 29.72, 24.56; LC/MS (ESI, <i>m</i>/<i>z</i>) 444.2136 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-3-Amino-1-(3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one Hydrochloride (<b>17</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (d, <i>J</i> = 9.2 Hz, 1H), 7.67 (d, <i>J</i> = 7.8 Hz, 2H), 7.45 (t, <i>J</i> = 7.4 Hz, 2H), 7.28–7.08 (m, 5H), 4.80 (s, 0.5H), 4.70 (s, 0.5H), 4.58 (d, <i>J</i> = 11.9 Hz, 1H), 4.31 (d, <i>J</i> = 12.0 Hz, 0.5H), 4.02 (d, <i>J</i> = 12.2 Hz, 0.5H), 3.86 (d, <i>J</i> = 13.7 Hz, 1H), 3.72–3.53 (m, 1H), 3.17 (d, <i>J</i> = 9.9 Hz, 2H), 3.02 (m, 2H), 2.86 (d, <i>J</i> = 11.3 Hz, 1H), 2.80–2.60 (m, 2H), 2.25 (m, 0.5H), 2.14 (m, 0.5H), 1.91 (m, 1H), 1.64 (d, <i>J</i> = 47.2 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.92, 158.29, 156.50, 153.51, 151.97, 148.13, 146.51, 130.67, 126.51, 124.48, 119.58, 97.24, 53.16, 45.67, 35.63, 30.41, 29.90, 24.67, 23.56; LC/MS (ESI, <i>m</i>/<i>z</i>) 458.2321 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)propan-1-one Hydrochloride (<b>19</b>)</h4><div class="NLM_p last">Yield = 36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.68 (d, <i>J</i> = 7.7 Hz, 2H), 7.45 (d, <i>J</i> = 6.9 Hz, 2H), 7.17 (dd, <i>J</i> = 20.2, 8.4 Hz, 5H), 5.78 (s, 2H), 4.69 (m, 1H), 4.48 (m, 0.5H), 4.32 (m, 0.5H), 4.07 (d, <i>J</i> = 24.9 Hz, 1H), 3.91 (d, <i>J</i> = 27.4 Hz, 1H), 3.19 (m, 2H), 2.29 (m, 1H), 2.12 (d, <i>J</i> = 13.3 Hz, 1H), 1.96 (d, <i>J</i> = 36.0 Hz, 1H), 1.69 (m, 0.5H), 1.53 (m, 0.5H), 1.22 (d, <i>J</i> = 23.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.37, 168.90, 158.28, 156.49, 153.61, 152.28, 151.99, 148.10, 146.47, 130.66, 126.48, 124.44, 119.55, 97.19, 52.94, 49.15, 46.48, 29.67, 24.53, 21.63, 16.70; LC/MS (ESI, <i>m</i>/<i>z</i>) 458.2318 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>R</i>)-2-Amino-1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-3-hydroxypropan-1-one Hydrochloride (<b>20</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 2H), 7.45 (t, <i>J</i> = 7.3 Hz, 2H), 7.17 (dt, <i>J</i> = 10.1, 8.1 Hz, 5H), 4.81 (m, 0.5H), 4.67 (m, 1H), 4.56 (d, <i>J</i> = 11.3 Hz, 0.5H), 4.38 (m, 0.5H), 4.22 (d, <i>J</i> = 11.1 Hz, 0.5H), 4.08 (d, <i>J</i> = 11.6 Hz, 0.5H), 3.77 (m, 0.5H), 3.67 (s, 1H), 3.53–3.43 (m, 1H), 3.22–3.07 (m, 1H), 2.24 (s, 1H), 2.13 (s, 1H), 1.89 (s, 1H), 1.75 (s, 2H), 1.55 (s, 1H), 1.24 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.40, 166.39, 158.32, 156.49, 153.35, 152.18, 151.91, 147.91, 146.63, 130.68, 126.42, 124.47, 119.57, 97.22, 60.36, 53.06, 46.33, 29.87, 24.76, 21.61, 14.57; LC/MS (ESI, <i>m</i>/<i>z</i>) 474.2255 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-3-methylbutan-1-one Hydrochloride (<b>21</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 5.7 Hz, 1H), 7.69 (s, 2H), 7.45 (t, <i>J</i> = 7.5 Hz, 2H), 7.35–7.01 (m, 5H), 4.80 (s, 1H), 4.61 (d, <i>J</i> = 10.0 Hz, 1H), 4.34 (m, 1H), 4.18 (d, <i>J</i> = 11.0 Hz, 1H), 4.01 (m, 1H), 3.74–3.48 (m, 2H), 3.12 (d, <i>J</i> = 12.4 Hz, 2H), 2.85 (m, 1H), 2.28 (m, 1H), 2.15 (m, 1H), 1.94 (m, 1H), 1.78 (m, 1H), 1.58 (m, 1H), 1.08–0.64 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.37, 167.76, 158.26, 156.51, 153.84, 152.16, 148.58, 146.35, 130.64, 126.58, 124.44, 119.58, 97.26, 54.13, 49.42, 46.03, 29.96, 24.74, 21.62, 18.85, 17.87; LC/MS (ESI, <i>m</i>/<i>z</i>) 486.2625 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-3-hydroxybutan-1-one Hydrochloride (<b>22</b>)</h4><div class="NLM_p last">Yield = 36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.68 (d, <i>J</i> = 7.7 Hz, 2H), 7.45 (t, <i>J</i> = 7.1 Hz, 2H), 7.24–7.10 (m, 5H), 4.82 (s, 1H), 4.67 (s, 1H), 4.55 (d, <i>J</i> = 11.0 Hz, 1H), 4.39 (s, 1H), 4.25 (d, <i>J</i> = 11.6 Hz, 1H), 4.07 (d, <i>J</i> = 12.8 Hz, 1H), 3.81 (s, 1H), 3.68 (s, 1H), 3.20 (d, <i>J</i> = 11.4 Hz, 1.5H), 2.77 (s, 0.5H), 2.27 (d, <i>J</i> = 12.1 Hz, 1H), 2.13 (s, 1H), 1.89 (s, 1H), 1.71 (s, 0.5H), 1.56 (s, 0.5H), 1.08 (d, <i>J</i> = 25.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.62, 158.32, 156.50, 153.42, 151.97, 148.01, 146.60, 130.66, 126.46, 124.48, 119.57, 97.25, 66.24, 55.11, 53.15, 49.76, 46.28, 30.01, 24.82, 19.75; LC/MS (ESI, <i>m</i>/<i>z</i>) 488.2416 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2<i>R</i>,3<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-3-methylpentan-1-one Hydrochloride (<b>23</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 7.67 (d, <i>J</i> = 7.4 Hz, 2H), 7.45 (t, <i>J</i> = 7.1 Hz, 2H), 7.32–7.03 (m, 5H), 4.70 (s, 1H), 4.47 (d, <i>J</i> = 53.8 Hz, 1H), 4.04 (d, <i>J</i> = 77.1 Hz, 1H), 2.81 (s, 1H), 2.21 (d, <i>J</i> = 57.3 Hz, 2H), 1.90 (s, 1H), 1.72 (s, 1H), 1.52 (s, 3H), 1.24 (m, 1H), 1.04 (d, <i>J</i> = 6.1 Hz, 2H), 1.00–0.70 (m, 7H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.78, 158.22, 156.54, 154.01, 152.24, 148.86, 146.25, 130.64, 126.69, 124.43, 119.54, 97.31, 53.74, 52.98, 46.21, 36.57, 30.00, 24.78, 24.01, 21.60, 14.99, 11.89; LC/MS (ESI, <i>m</i>/<i>z</i>) 500.2741 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-4-methylpentan-1-one Hydrochloride (<b>24</b>)</h4><div class="NLM_p last">Yield = 36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 7.68 (s, 2H), 7.45 (d, <i>J</i> = 7.1 Hz, 2H), 7.16 (dd, <i>J</i> = 16.8, 7.8 Hz, 5H), 4.99 (s, 0.5H), 4.83–4.57 (m, 1.5H), 4.47–4.19 (m, 2H), 4.11 (d, <i>J</i> = 12.3 Hz, 1H), 3.87 (d, <i>J</i> = 12.9 Hz, 1H), 3.71 (d, <i>J</i> = 10.7 Hz, 0.5H), 3.31–3.10 (m, 1H), 2.97 (s, 0.5H), 2.25 (d, <i>J</i> = 37.3 Hz, 2H), 1.92 (t, <i>J</i> = 29.0 Hz, 2H), 1.71 (s, 2H), 1.56 (s, 1H), 1.37–1.12 (m, 1H), 1.07–0.88 (m, 3H), 0.78 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.55, 158.25, 156.52, 154.25, 152.28, 148.74, 146.42, 130.64, 126.66, 124.45, 119.56, 97.37 (s), 53.29, 49.21, 48.63, 45.98, 45.49, 42.47, 29.76, 23.70, 22.38; LC/MS (ESI, <i>m</i>/<i>z</i>) 500.2731 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>R</i>)-2-Amino-1-(4-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)-4-methylpentan-1-one Hydrochloride (<b>28</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.25 (s, 3H), 7.66 (d, <i>J</i> = 7.3 Hz, 2H), 7.46 (t, <i>J</i> = 7.4 Hz, 2H), 7.31–7.05 (m, 5H), 5.11 (s, 1H), 4.51 (d, <i>J</i> = 15.0 Hz, 2H), 3.95 (s, 2H), 3.43 (d, <i>J</i> = 12.8 Hz, 2H), 3.01 (d, <i>J</i> = 31.8 Hz, 1H), 2.26 (s, 1H), 2.10 (d, <i>J</i> = 37.1 Hz, 3H), 1.79 (s, 1H), 1.62 (s, 1H), 1.51 (s, 1H), 1.01–0.80 (m, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.23, 158.22, 156.50, 154.00, 151.80, 148.64, 146.13, 130.65, 126.70, 124.45, 119.55 62, 119.49, 97.28, 54.39, 48.48, 44.30, 31.85, 23.88, 23.48, 22.31; LC/MS (ESI, <i>m</i>/<i>z</i>) 500.2768 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>R</i>)-2-Amino-1-(3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)pyrrolidin-1-yl)ethanone Hydrochloride (<b>29</b>)</h4><div class="NLM_p last">Yield = 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64 (s, 1H), 7.69 (s, 2H), 7.46 (t, <i>J</i> = 6.8 Hz, 2H), 7.17 (dd, <i>J</i> = 22.0, 10.8 Hz, 5H), 5.61 (d, <i>J</i> = 22.8 Hz, 1H), 4.12–3.55 (m, 7H), 2.50–2.29 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.39, 164.83, 158.37, 156.43, 153.29, 152.03, 147.81, 146.72, 130.99, 126.34, 124.50, 119.83, 97.38, 56.56, 50.83, 45.20, 29.80; LC/MS (ESI, <i>m</i>/<i>z</i>) 430.1983 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>R</i>)-2-Amino-1-((<i>R</i>)-3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)pyrrolidin-1-yl)-4-methylpentan-1-one Hydrochloride (<b>31</b>)</h4><div class="NLM_p last">Yield = 36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (s, 1H), 7.67 (dd, <i>J</i> = 25.2, 8.5 Hz, 2H), 7.46 (s, 2H), 7.31–7.05 (m, 5H), 5.63 (s, 1H), 4.19 (d, <i>J</i> = 30.6 Hz, 2H), 4.05 (m, 2H), 3.92 (m, 2H), 3.66 (m, 2H), 1.58 (d, <i>J</i> = 57.3 Hz, 2H), 0.95 (dd, <i>J</i> = 13.0, 6.2 Hz, 3H), 0.76 (d, <i>J</i> = 6.0 Hz, 2H), 0.69 (d, <i>J</i> = 6.3 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.77, 158.26, 156.51, 154.05, 152.26, 149.05, 146.26, 130.78, 130.57, 126.61, 124.48, 119.64, 119.55, 97.53, 56.79, 54.81, 50.73, 49.76, 45.47, 31.55, 29.91, 23.76; LC/MS (ESI, <i>m</i>/<i>z</i>) 486.2611 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Modeling Method</h3><div class="NLM_p last">The FLT3 DFG-in conformation was obtained from a DFG-peptide modification based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> which is a released FLT3 protein structure with DFG-out conformation. The modification was to carry out a short molecular dynamics modeling (1.0 ns) with the restraints on DFG peptide to induce a DFG-in mode. Here the restrained molecular dynamics was run using TINKER 4.2<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with amber99 force field.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Then from the trajectory of FLT3 DFG-in conformations, a conformation with the minimum rmsd compared with the PDB structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a> was used as our FLT3 DFG-in conformation. Then PCI32765 was docked into BTK kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>) and FLT3 DFG-in conformation, respectively, using Autodock4.0 with AutoDocktool<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Compound <b>18</b> was also docked into the FLT3 DFG-in conformation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). In the docking protocol, the Lamarchian genetic algorithm (GA) and the default parameters of GA were applied except that the population size was set to 100 and the rate of gene mutation was set to 0.2. The docked complexes were then clustered and sorted according to the binding energy, and the binding model with the lowest binding energy was used to further reveal the binding mechanism.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Cell Culture and Proliferation Study</h3><div class="NLM_p">The human AML cell lines MV4-11, U937 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The FLT3-ITD-expressing lines, MOLM-13, MOLM14, were provided by Dr. Scott Armstrong, Dana Farber Cancer Institute (DFCI), Boston, MA. MV4-11 was cultured in IMDM media (Corning, USA) with 10% FBS and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% pen/strep. MOLM-13, MOLM-14, U937, and FLT3 mutant isogenic BaF3 cells lines were cultured in RPMI 1640 media (Corning, USA) with 10% fetal bovine serum (FBS) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine 1% penicillin/streptomycin. All cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>.</div><div class="NLM_p last">Cells were grown in 96-well culture plates (3000/well). The compounds of various concentrations were added into the plates. Cell proliferation was determined after treatment with compounds for 72 h. Cell viability was measured using the CellTiter-Glo assay (Promega, USA) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (Envision, PerkinElmer, USA). Data were normalized to control groups (DMSO) and represented by the mean of three independent measurements with standard error of <20%. GI<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Signaling Pathway Study</h3><div class="NLM_p last">MOLM13, MOLM14, MV4-11 cells were treated with DMSO, serially diluted compound <b>18</b>, 0.1 μM AC220 for 4 h. Cells were then washed in PBS and lysed in cell lysis buffer. FLT3, Phospho-FLT3(Tyr589/591), STAT5, Phospho-STAT5 (Tyr694), AKT, Phospho-AKT Ser473, Phospho-AKT ERK, Phospho-p44/42MAPK(Erk1/2) (Thr202/Tyr204), C-Myc, and GAPDH antibody (Cell signaling Technology) were used for immunoblotting.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Apoptosis Effect Examination</h3><div class="NLM_p last">MOLM13, MOLM14, MV4-11 cells were treated with DMSO, serially diluted compound <b>18</b>, 0.1 μM AC220 for the indicated periods. Cells were then washed in PBS and lysed in cell lysis buffer. PARP, caspase-3, GAPDH antibody (Cell Signaling Technology) were used for immunoblotting.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Cell Cycle Analysis</h3><div class="NLM_p last">MOLM13, MOLM14, MV4-11 cells were treated with DMSO, serially diluted compound <b>18</b>, 0.1 μM AC220 for the indicated periods. The cells were fixed in 70% cold ethanol and incubated at −20 °C overnight and then stained with PI/RNase staining buffer (BD Pharmingen). Flow cytometry was performed using a FACS Calibur (BD), and the results were analyzed by ModFit software.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> In Vivo Pharmacodynamics Study</h3><div class="NLM_p last">Compound <b>18</b> was dissolved in 55% saline containing 5% DMSO and 40% PEG400 by vortex. The final concentration of the stock solution was 1 mg/mL for administration. Twenty-four 6–8 weeks old male Sprague-Dawely rats were fasted overnight before starting drug treatment via intravenous and oral administration. Animal blood collection time points were as follows: for groups 1, 3, 5 (intravenous), 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h before and after administration were selected; for groups 2, 4, 6 (oral), 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h before and after dosing were selected. Each time about 0.2 mL of blood was collected through the jugular vein adding heparin for anticoagulation and kept on ice. Then plasma was separated by centrifugation at 8000 rpm for 6 min at 2–8 °C. The obtained plasma was stored at −80 °C before analysis. After the test was finished, all surviving animals were transferred to the repository or euthanaized (CO<sub>2</sub> asphyxiation).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> MV4-11 Xenograft Tumor Model</h3><div class="NLM_p last">Five-week-old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). All animals were housed in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). Prior to implantation, cells were harvested during exponential growth. Five million MV4-11 cells in PBS were formulated as a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily oral administration was initiated when MV4-11 tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of 5 mice each for efficacy studies. Compound <b>18</b> was delivered daily in a HKI solution (0.5% methocellulose/0.4% Tween80 in ddH<sub>2</sub>O) by oral gavage. A range of doses of compound <b>18</b> or its vehicle were administered, as indicated in the <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> caption. Body weight was measured daily, and tumor growth was measured every other day after compound <b>18</b> treatment. Tumor volume was calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d87e4746-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01611">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01611" class="ext-link">10.1021/acs.jmedchem.5b01611</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding data of compound <b>18</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01611/suppl_file/jm5b01611_si_001.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01611/suppl_file/jm5b01611_si_001.xlsx">jm5b01611_si_001.xlsx (497.87 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01611" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#660c0f08010a0f13260e0b000a480705480508"><span class="__cf_email__" data-cfemail="dbb1b2b5bcb7b2ae9bb3b6bdb7f5bab8f5b8b5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of
China, Hefei 230036, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei Science Center, Chinese Academy of Sciences, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6110120d0814585621090c070d4f00024f020f"><span class="__cf_email__" data-cfemail="0f7e7c63667a36384f67626963216e6c216c61">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xixiang Li</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of
China, Hefei 230036, Anhui, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of
China, Hefei 230036, Anhui, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Wu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of
China, Hefei 230036, Anhui, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiaxin Wu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">University of Science and Technology of
China, Hefei 230036, Anhui, P. R.
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Zhao</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Liu</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">High Magnetic Field
Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R.
China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanchun Zhang</span> - <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei Cosource Medicine Technology Co. Ltd., 358 Ganquan Road, Hefei 230031, Anhui, P. R.
China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.L., A.W., K.Y., and Z.Q. contribute equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>∇</sup>S.Z. is a shareholder of Hefei Cosource Medicine Technology Co. Ltd.<br /></br></div></li></ul></div><div class="ack" id="ACK-d87e4743-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Scientific Research Grant of Hefei Science Center of CAS (SRG-HSC Grant 2015SRG-HSC022). Q.L., J.L., and W.W. are supported by the grant “Cross-Disciplinary Collaborative Teams Program for Science, Technology and Innovation (2014–2016)” from Chinese Academy of Sciences. Z.Z. is supported by Anhui Province Natural Science Foundation Annual Key Program (Grant 1301023011). We thank China “Thousand Talents Program” support for Q.L. and “Hundred Talents Program” of the Chinese Academy of Sciences support for J.L. and W.W.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i69" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i69"> Abbreviations Used</h2><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase</p></td></tr><tr><td class="NLM_term">FLT3-ITD</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase internal tandem duplication</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lowenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span> </span><span class="NLM_article-title">Acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1062</span><span class="refDoi"> DOI: 10.1056/NEJM199909303411407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1056%2FNEJM199909303411407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10502596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1051-1062&author=B.+Lowenbergauthor=J.+R.+Downingauthor=A.+Burnett&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJM199909303411407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukemia</span></div><div class="casAuthors">Lowenberg B; Downing J R; Burnett A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1051-62</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvdpRq9xav842y4bB4mnvYfW6udTcc2eZh4n3fLMlI4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D&md5=7cd5e8c3edc8a431afbad11822153c23</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909303411407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909303411407%26sid%3Dliteratum%253Aachs%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DBurnett%26aufirst%3DA.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D1051%26epage%3D1062%26doi%3D10.1056%2FNEJM199909303411407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">American Cancer Society</span>. <span> </span><span class="NLM_article-title">Cancer Facts & Figures 2013</span>. <span class="NLM_publisher-name">American Cancer Society</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=American+Cancer+Society.+Cancer+Facts+%26+Figures+2013.+American+Cancer+Society%3A+Atlanta%2C+GA%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DCancer%2520Facts%2520%2526%2520Figures%25202013%26pub%3DAmerican%2520Cancer%2520Society%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Markovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span> </span><span class="NLM_article-title">FLT-3: a new focus in the understanding of acute leukemia</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1168</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1016/j.biocel.2004.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1016%2Fj.biocel.2004.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=15778081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlChtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=1168-1172&author=A.+Markovicauthor=K.+L.+MacKenzieauthor=R.+B.+Lock&title=FLT-3%3A+a+new+focus+in+the+understanding+of+acute+leukemia&doi=10.1016%2Fj.biocel.2004.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">FLT-3: a new focus in the understanding of acute leukemia</span></div><div class="casAuthors">Markovic, Ana; MacKenzie, Karen L.; Lock, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1168-1172</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The FMS-like tyrosine kinase-3 (FLT-3), which belongs to the class III receptor tyrosine kinase family, is primarily expressed by hematopoietic cells and plays an important role in hematopoiesis.  FLT-3 is also expressed in the majority of acute leukemias, in which the presence of FLT-3 activating mutations is assocd. with poor prognosis.  Consequently, there has been a recent surge in the development of FLT-3 inhibitors for the mol. targeting of leukemia, and many of these are now in clin. trials.  An improved understanding of how FLT-3 interacts with its ligand, as well as how FLT-3 activating mutations are able to trigger downstream intracellular signaling pathways, will provide greater insight to how small mol. inhibitors may best be utilized and combined with established chemotherapeutic drugs for the management of patients with high-risk acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLss2loIUqOrVg90H21EOLACvtfcHk0lg6KkrK_WhUDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlChtLc%253D&md5=e36257ac7cb03ee603de0a87292b6f54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2004.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2004.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMarkovic%26aufirst%3DA.%26aulast%3DMacKenzie%26aufirst%3DK.%2BL.%26aulast%3DLock%26aufirst%3DR.%2BB.%26atitle%3DFLT-3%253A%2520a%2520new%2520focus%2520in%2520the%2520understanding%2520of%2520acute%2520leukemia%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2005%26volume%3D37%26spage%3D1168%26epage%3D1172%26doi%3D10.1016%2Fj.biocel.2004.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span><span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lg6KkrK_WhUDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1532/IJH97.05079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors&doi=10.1532%2FIJH97.05079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0ljJKfbjW0vQFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107%26doi%3D10.1532%2FIJH97.05079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0ljJKfbjW0vQFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yoshimoto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbarzadeh-Tabrizi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocnik, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikushige, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagafuji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akashi, K.</span><span> </span><span class="NLM_article-title">FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">5034</span><span class="NLM_x">–</span> <span class="NLM_lpage">5043</span><span class="refDoi"> DOI: 10.1182/blood-2008-12-196055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2008-12-196055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5034-5043&author=G.+Yoshimotoauthor=T.+Miyamotoauthor=S.+Jabbarzadeh-Tabriziauthor=T.+Iinoauthor=J.+L.+Rocnikauthor=Y.+Kikushigeauthor=Y.+Moriauthor=T.+Shimaauthor=H.+Iwasakiauthor=K.+Takenakaauthor=K.+Nagafujiauthor=S.+Mizunoauthor=H.+Niiroauthor=G.+D.+Gillilandauthor=K.+Akashi&title=FLT3-ITD+up-regulates+MCL-1+to+promote+survival+of+stem+cells+in+acute+myeloid+leukemia+via+FLT3-ITD-specific+STAT5+activation&doi=10.1182%2Fblood-2008-12-196055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-196055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-196055%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DJabbarzadeh-Tabrizi%26aufirst%3DS.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DRocnik%26aufirst%3DJ.%2BL.%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DShima%26aufirst%3DT.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DS.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DGilliland%26aufirst%3DG.%2BD.%26aulast%3DAkashi%26aufirst%3DK.%26atitle%3DFLT3-ITD%2520up-regulates%2520MCL-1%2520to%2520promote%2520survival%2520of%2520stem%2520cells%2520in%2520acute%2520myeloid%2520leukemia%2520via%2520FLT3-ITD-specific%2520STAT5%2520activation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5034%26epage%3D5043%26doi%3D10.1182%2Fblood-2008-12-196055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span><span class="refDoi"> DOI: 10.1182/blood-2002-07-2307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2002-07-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=12531805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2002-07-2307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Abrams, Tinya J.; Yuen, Helene A.; Ngai, Theresa J.; Louie, Sharianne G.; Yee, Kevin W. H.; Wong, Lily M.; Hong, Weiru; Lee, Leslie B.; Town, Ajia; Smolich, Beverly D.; Manning, William C.; Murray, Lesley J.; Heinrich, Michael C.; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3597-3605</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells.  In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have been identified: internal tandem duplication (ITD) mutations in the juxtamembrane domain (25%-30% of patients) and point mutations in the kinase domain activation loop (7%-8% of patients).  FLT3-ITD mutations are the most common mol. defect identified in AML and have been shown to be an independent prognostic factor for decreased survival.  FLT3-ITD is therefore an attractive mol. target for therapy.  SU11248 is a recently described selective inhibitor with selectivity for split kinase domain RTKs, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT.  We show that SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation assays.  SU11248 inhibits FLT3-driven phosphorylation and induces apoptosis in vitro.  In addn., SU11248 inhibits FLT3-induced VEGF prodn.  The in vivo efficacy of SU11248 was investigated in 2 FLT3-ITD models: a s.c. tumor xenograft model and a bone marrow engraftment model.  We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the s.c. tumor xenograft model and prolongs survival in the bone marrow engraftment model.  Pharmacokinetic and pharmacodynamic anal. in s.c. tumors showed that a single administration of an efficacious drug dose potently inhibits FLT3-ITD phosphorylation for up to 16 h following a single dose.  These results suggest that further exploration of SU11248 activity in AML patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUcmQRlrUD7Vg90H21EOLACvtfcHk0ljHkNYccba6pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D&md5=f996fe320ccf9449951baf97e372c694</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-07-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-07-2307%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605%26doi%3D10.1182%2Fblood-2002-07-2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1093/jnci/djm328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quintas-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia&doi=10.1093%2Fjnci%2Fdjm328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0ljHkNYccba6pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198%26doi%3D10.1093%2Fjnci%2Fdjm328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S89</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=S89-90&issue=Suppl.+1&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=A.+Yapauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=PKC+412+FLT3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520FLT3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26issue%3DSuppl.%25201%26spage%3DS89%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span><span class="refDoi"> DOI: 10.1182/blood-2003-11-3775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2003-11-3775" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia&doi=10.1182%2Fblood-2003-11-3775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-11-3775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-11-3775%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676%26doi%3D10.1182%2Fblood-2003-11-3775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaros, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7031</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span><span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0li3nUOi5071aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1182/blood-2006-02-005702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.+M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics&doi=10.1182%2Fblood-2006-02-005702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0li3nUOi5071aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.%2BM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681%26doi%3D10.1182%2Fblood-2006-02-005702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span><span class="refDoi"> DOI: 10.1182/blood-2009-01-199307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2009-01-199307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation&doi=10.1182%2Fblood-2009-01-199307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-01-199307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-01-199307%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617%26doi%3D10.1182%2Fblood-2009-01-199307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenreid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deignan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huard, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizerman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMinn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalic, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattabiraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragains, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchomel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickramasinghe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lj6_y28ih4Wuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeschke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5319</span><span class="NLM_x">–</span> <span class="NLM_lpage">5324</span><span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugitaauthor=M.+Carrollauthor=S.+C.+Koganauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0liFcIb2Hke6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carias, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matusow, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+Overriding+the+Structural+Mechanism+of+the+Quizartinib-Resistant+FLT3+%E2%80%9CGatekeeper%E2%80%9D+F691L+Mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0liFcIb2Hke6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520Overriding%2520the%2520Structural%2520Mechanism%2520of%2520the%2520Quizartinib-Resistant%2520FLT3%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520F691L%2520Mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Warkentin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A. Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Overcoming Myelosuppression Due to Synthetic Lethal Toxicity in FLT3-Targeted Acute Myeloid Leukemia Therapy</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="refDoi"> DOI: 10.7554/eLife.03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.7554%2FeLife.03445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=3&author=A.+A.+Warkentinauthor=M.+S.+Lopezauthor=E.+A.+Lasaterauthor=K.+Linauthor=B.+L.+Heauthor=A.+Y.+H.+Leungauthor=C.+C.+Smithauthor=N.+P.+Shahauthor=K.+M.+Shokat&title=Overcoming+Myelosuppression+Due+to+Synthetic+Lethal+Toxicity+in+FLT3-Targeted+Acute+Myeloid+Leukemia+Therapy&doi=10.7554%2FeLife.03445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.7554%2FeLife.03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.03445%26sid%3Dliteratum%253Aachs%26aulast%3DWarkentin%26aufirst%3DA.%2BA.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DB.%2BL.%26aulast%3DLeung%26aufirst%3DA.%2BY.%2BH.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DOvercoming%2520Myelosuppression%2520Due%2520to%2520Synthetic%2520Lethal%2520Toxicity%2520in%2520FLT3-Targeted%2520Acute%2520Myeloid%2520Leukemia%2520Therapy%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3D3%26doi%3D10.7554%2FeLife.03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3286</span><span class="NLM_x">–</span> <span class="NLM_lpage">3293</span><span class="refDoi"> DOI: 10.1182/blood-2010-01-266742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2010-01-266742" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3286-3293&author=T.+Satoauthor=X.+Yangauthor=S.+Knapperauthor=P.+Whiteauthor=B.+D.+Smithauthor=S.+Galkinauthor=D.+Smallauthor=A.+Burnettauthor=M.+Levis&title=FLT3+ligand+impedes+the+efficacy+of+FLT3+inhibitors+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-266742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-266742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-266742%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGalkin%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%2520ligand%2520impedes%2520the%2520efficacy%2520of%2520FLT3%2520inhibitors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D3286%26epage%3D3293%26doi%3D10.1182%2Fblood-2010-01-266742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. S.</span><span> </span><span class="NLM_article-title">A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib</span> <span class="citation_source-journal">J. Oncol. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1177/1078155214561281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1177%2F1078155214561281" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+S.+Leeauthor=M.+A.+Rattuauthor=S.+S.+Kim&title=A+review+of+a+novel%2C+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+ibrutinib&doi=10.1177%2F1078155214561281"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F1078155214561281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155214561281%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DRattu%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BS.%26atitle%3DA%2520review%2520of%2520a%2520novel%252C%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520ibrutinib%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2014%26doi%3D10.1177%2F1078155214561281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1038/leu.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1038%2Fleu.2015.175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Wuauthor=C.+Huauthor=A.+Wangauthor=E.+L.+Weisbergauthor=W.+Wangauthor=C.+Chenauthor=Z.+Zhaoauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=A.+Nonamiauthor=L.+Wangauthor=B.+Wangauthor=R.+M.+Stoneauthor=S.+Liuauthor=J.+D.+Griffinauthor=Q.+Liu&title=Ibrutinib+selectively+targets+FLT3-ITD+in+mutant+FLT3-positive+AML&doi=10.1038%2Fleu.2015.175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520targets%2520FLT3-ITD%2520in%2520mutant%2520FLT3-positive%2520AML%26jtitle%3DLeukemia%26date%3D2015%26doi%3D10.1038%2Fleu.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lhG6PpFBdfK5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>TINKER Molecular Modeling. TINKER—Software Tools for Molecular Design. <a href="http://dasher.wustl.edu/tinker/" class="extLink">http://dasher.wustl.edu/tinker/</a> (updated May 12,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=TINKER+Molecular+Modeling.+TINKER%E2%80%94Software+Tools+for+Molecular+Design.+http%3A%2F%2Fdasher.wustl.edu%2Ftinker%2F+%28updated+May+12%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strockbine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmerling, C.</span><span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of α-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./ψ dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./ψ dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0lh8fqXtbejrnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halliday, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADyaK1cXntFemur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=1639-1662&author=G.+M.+Morrisauthor=D.+S.+Goodsellauthor=R.+S.+Hallidayauthor=R.+Hueyauthor=W.+E.+Hartauthor=R.+K.+Belewauthor=A.+J.+Olson&title=Automated+docking+using+a+Lamarckian+genetic+algorithm+and+an+empirical+binding+free+energy+function&doi=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function</span></div><div class="casAuthors">Morris, Garrett M.; Goodsell, David S.; Halliday, Robert S.; Huey, Ruth; Hart, William E.; Belew, Richard K.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1639-1662</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review, with 81 refs.  A novel and robust automated docking method that predicts the bound conformations of flexible ligands to macromol. targets has been developed and tested, in combination with a new scoring function that ests. the free energy change upon binding.  Interestingly, this method applies a Lamarckian model of genetics, in which environmental adaptations of an individual's phenotype are reverse transcribed into its genotype and become heritable traits (sic).  We consider three search methods, Monte Carlo simulated annealing, a traditional genetic algorithm, and the Lamarckian genetic algorithm, and compare their performance in dockings of seven protein-ligand test systems having known three-dimensional structure.  We show that both the traditional and Lamarckian genetic algorithms can handle ligands with more degrees of freedom than the simulated annealing method used in earlier versions of AuToDOCK, and that the Lamarckian genetic algorithm is the most efficient, reliable, and successful of the three.  The empirical free energy function was calibrated using a set of 30 structurally known protein-ligand complexes with exptl. detd. binding consts.  Linear regression anal. of the obsd. binding consts. in terms of a wide variety of structure-derived mol. properties was performed.  The final model had a residual std. error of 9.11 kJ mol-1 (2.177 kcal mol-1) and was chosen as the new energy function.  The new search methods and empirical free energy function are available in AUTODOCK, version 3.0.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXZfPvnZWcbVg90H21EOLACvtfcHk0lh8fqXtbejrnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFemur4%253D&md5=804b9f797c0b2cf942444c17b5653659</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-987X%252819981115%252919%253A14%253C1639%253A%253AAID-JCC10%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DHalliday%26aufirst%3DR.%2BS.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DW.%2BE.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutomated%2520docking%2520using%2520a%2520Lamarckian%2520genetic%2520algorithm%2520and%2520an%2520empirical%2520binding%2520free%2520energy%2520function%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1998%26volume%3D19%26spage%3D1639%26epage%3D1662%26doi%3D10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Xiang Pan, Yi Song, Jian Liu, Fei Ma, Ping Wang, Yan Liu, Lin Zhao, Di Kang, <span class="NLM_string-name hlFld-ContribAuthor">Lihong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4870-4890. <a href="https://doi.org/10.1021/acs.jmedchem.0c02247" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02247%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BFLT3%252BInhibitor%252B%252528Z%252529-N-%2525285-%252528%2525285-Fluoro-2-oxoindolin-3-ylidene%252529methyl%252529-4-methyl-1H-pyrrol-3-yl%252529-3-%252528pyrrolidin-1-yl%252529propanamide%252Bwith%252BImproved%252BDrug-like%252BProperties%252Band%252BSuperior%252BEfficacy%252Bin%252BFLT3-ITD-Positive%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28122020%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D4870%26epage%3D4890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xue Yuan, Yong Chen, Wanhua Zhang, Jun He, Lei Lei, Minghai Tang, Jiang Liu, Muzhou Li, Caixia Dou, Tao Yang, Linyu Yang, Shengyong Yang, Yuquan Wei, Aihua Peng, Ting Niu, Mingli Xiang, Haoyu Ye, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 4158-4173. <a href="https://doi.org/10.1021/acs.jmedchem.9b00223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-Based%252BDerivatives%252Bas%252BPotent%252Band%252BOrally%252BEffective%252BFms-like%252BTyrosine%252BReceptor%252BKinase%252B3%252B%252528FLT3%252529%252BInhibitors%252Bfor%252BTreating%252BAcute%252BMyelogenous%252BLeukemia%26aulast%3DYuan%26aufirst%3DXue%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02022019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D8%26spage%3D4158%26epage%3D4173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaofei Liang, Beilei Wang, Cheng Chen, Aoli Wang, Chen Hu, Fengming Zou, Kailin Yu, Qingwang Liu, Feng Li, Zhenquan Hu, Tingting Lu, Junjie Wang, Li Wang, Ellen L. Weisberg, Lili Li, Ruixiang Xia, Wenchao Wang, Tao Ren, Jian Ge, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Qingsong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 875-892. <a href="https://doi.org/10.1021/acs.jmedchem.8b01594" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%2525284-%2525286-Acetamidopyrimidin-4-yloxy%252529phenyl%252529-2-%2525282-%252528trifluoromethyl%252529phenyl%252529acetamide%252B%252528CHMFL-FLT3-335%252529%252Bas%252Ba%252BPotent%252BFMS-like%252BTyrosine%252BKinase%252B3%252BInternal%252BTandem%252BDuplication%252B%252528FLT3-ITD%252529%252BMutant%252BSelective%252BInhibitor%252Bfor%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D13102018%26date%3D08012019%26date%3D19122018%26volume%3D62%26issue%3D2%26spage%3D875%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, and <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8407-8424. <a href="https://doi.org/10.1021/acs.jmedchem.7b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%2525284-%2525284-Amino-3-%2525284-%2525282-morpholinoethoxy%252529phenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529phenyl%252529-3-%2525285-%252528tert-butyl%252529isoxazol-3-yl%252529urea%252B%252528CHMFL-FLT3-213%252529%252Bas%252Ba%252BHighly%252BPotent%252BType%252BII%252BFLT3%252BKinase%252BInhibitor%252BCapable%252Bof%252BOvercoming%252Ba%252BVariety%252Bof%252BFLT3%252BKinase%252BMutants%252Bin%252BFLT3-ITD%252BPositive%252BAML%26aulast%3DWang%26aufirst%3DAoli%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08062017%26date%3D17102017%26date%3D26102017%26date%3D28092017%26volume%3D60%26issue%3D20%26spage%3D8407%26epage%3D8424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Xiao-E  Yan</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, and <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2944-2962. <a href="https://doi.org/10.1021/acs.jmedchem.6b01907" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01907</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-1-%2525283-%2525284-Amino-3-%2525283-chloro-4-%252528pyridin-2-ylmethoxy%252529phenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529piperidin-1-yl%252529prop-2-en-1-one%252B%252528CHMFL-EGFR-202%252529%252Bas%252Ba%252BNovel%252BIrreversible%252BEGFR%252BMutant%252BKinase%252BInhibitor%252Bwith%252Ba%252BDistinct%252BBinding%252BMode%26aulast%3DWang%26aufirst%3DAoli%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D28122016%26date%3D22032017%26date%3D13042017%26date%3D10032017%26volume%3D60%26issue%3D7%26spage%3D2944%26epage%3D2962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ru  Dong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhou</span>, <span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Li</span>, <span class="hlFld-ContribAuthor ">Jin-Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zheng</span>, <span class="hlFld-ContribAuthor ">Kai-Xiang  Tang</span>, <span class="hlFld-ContribAuthor ">Li-Ping  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115876. <a href="https://doi.org/10.1016/j.bmc.2020.115876" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115876%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-amino-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin%252Bderivatives%252Bas%252Bnovel%252Bdiscoidin%252Bdomain%252Breceptor%252B1%252B%252528DDR1%252529%252Binhibitors%26aulast%3DDong%26aufirst%3DRu%26date%3D2021%26volume%3D29%26spage%3D115876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You-Guang  Zheng</span>, <span class="hlFld-ContribAuthor ">Wu-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Long  Meng</span>, <span class="hlFld-ContribAuthor ">Xiao-Qing  Wu</span>, <span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  An</span>, <span class="hlFld-ContribAuthor ">Cheng-Lin  Li</span>, <span class="hlFld-ContribAuthor ">Cai-Yun  Gao</span>, <span class="hlFld-ContribAuthor ">Liang  Xu</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112522. <a href="https://doi.org/10.1016/j.ejmech.2020.112522" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112522%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-aniline%252Bquinazoline%252Bderivatives%252Bconjugated%252Bwith%252Bhydrogen%252Bsulfide%252B%252528H2S%252529%252Bdonors%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bagainst%252BL858R%252Bresistance%252Bmutation%26aulast%3DZheng%26aufirst%3DYou-Guang%26date%3D2020%26volume%3D202%26spage%3D112522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatma A.  Ragab</span>, <span class="hlFld-ContribAuthor ">Yassin M.  Nissan</span>, <span class="hlFld-ContribAuthor ">Emad M.  Seif</span>, <span class="hlFld-ContribAuthor ">Ahmed  Maher</span>, <span class="hlFld-ContribAuthor ">Reem K.  Arafa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro investigation of novel cytotoxic pyrimidine and pyrazolopyrimidne derivatives showing apoptotic effect. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103621. <a href="https://doi.org/10.1016/j.bioorg.2020.103621" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103621%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Binvestigation%252Bof%252Bnovel%252Bcytotoxic%252Bpyrimidine%252Band%252Bpyrazolopyrimidne%252Bderivatives%252Bshowing%252Bapoptotic%252Beffect%26aulast%3DRagab%26aufirst%3DFatma%2BA.%26date%3D2020%26volume%3D96%26spage%3D103621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saul  Jaime-Figueroa</span>, <span class="hlFld-ContribAuthor ">Alexandru D.  Buhimschi</span>, <span class="hlFld-ContribAuthor ">Momar  Toure</span>, <span class="hlFld-ContribAuthor ">John  Hines</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (3)
                                     , 126877. <a href="https://doi.org/10.1016/j.bmcl.2019.126877" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126877%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BProteolysis%252BTargeting%252BChimeras%252B%252528PROTACs%252529%252Bas%252Ba%252BBTK%252Bdegraders%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%26aulast%3DJaime-Figueroa%26aufirst%3DSaul%26date%3D2020%26volume%3D30%26issue%3D3%26spage%3D126877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fansheng  Ran</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Meixia  Liu</span>, <span class="hlFld-ContribAuthor ">Daoguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Junze  Dong</span>, <span class="hlFld-ContribAuthor ">Wendi  Tang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>89 </em>, 102943. <a href="https://doi.org/10.1016/j.bioorg.2019.102943" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.102943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.102943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.102943%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BBTK%252Binhibitors%252Bwith%252Beffective%252Banticancer%252Bactivity%252Bin%252BMCL%26aulast%3DRan%26aufirst%3DFansheng%26date%3D2019%26volume%3D89%26spage%3D102943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaitlin C.  Fogg</span>, <span class="hlFld-ContribAuthor ">Will R.  Olson</span>, <span class="hlFld-ContribAuthor ">Jamison N.  Miller</span>, <span class="hlFld-ContribAuthor ">Aisha  Khan</span>, <span class="hlFld-ContribAuthor ">Carine  Renner</span>, <span class="hlFld-ContribAuthor ">Isaac  Hale</span>, <span class="hlFld-ContribAuthor ">Paul S.  Weisman</span>, <span class="hlFld-ContribAuthor ">Pamela K.  Kreeger</span>. </span><span class="cited-content_cbyCitation_article-title">Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>458 </em>, 92-101. <a href="https://doi.org/10.1016/j.canlet.2019.05.029" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.05.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.05.029%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DAlternatively%252Bactivated%252Bmacrophage-derived%252Bsecretome%252Bstimulates%252Bovarian%252Bcancer%252Bspheroid%252Bspreading%252Bthrough%252Ba%252BJAK2%25252FSTAT3%252Bpathway%26aulast%3DFogg%26aufirst%3DKaitlin%2BC.%26date%3D2019%26volume%3D458%26spage%3D92%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Balachandran</span>, <span class="hlFld-ContribAuthor ">Y.  Arun</span>, <span class="hlFld-ContribAuthor ">B.  Sangeetha</span>, <span class="hlFld-ContribAuthor ">V.  Duraipandiyan</span>, <span class="hlFld-ContribAuthor ">S.  Awale</span>, <span class="hlFld-ContribAuthor ">N.  Emi</span>, <span class="hlFld-ContribAuthor ">S.  Ignacimuthu</span>, <span class="hlFld-ContribAuthor ">P.T.  Perumal</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro and in vivo anticancer activity of 2-acetyl-benzylamine isolated from Adhatoda vasica L. leaves. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2017,</strong> <em>93 </em>, 796-806. <a href="https://doi.org/10.1016/j.biopha.2017.06.096" title="DOI URL">https://doi.org/10.1016/j.biopha.2017.06.096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2017.06.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2017.06.096%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DIn%252Bvitro%252Band%252Bin%252Bvivo%252Banticancer%252Bactivity%252Bof%252B2-acetyl-benzylamine%252Bisolated%252Bfrom%252BAdhatoda%252Bvasica%252BL.%252Bleaves%26aulast%3DBalachandran%26aufirst%3DC.%26date%3D2017%26volume%3D93%26spage%3D796%26epage%3D806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemcial structures of PCI-32765 (<b>1</b>) and CHMFL-FLT3-122 (<b>18</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode analysis of PCI-32765 (<b>1</b>) to BTK kinase and FLT3 kinase. (A) PCI-32765 docked into BTK kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>). (B) PCI-32765 docked into FLT3 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>). (C) Superimposition of BTK and FLT3 kinase in complex with PCI-32765 (purple, BTK kinase; white, FLT3 kinase). (D) Illustration of the chemical modification strategy of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>18</b> docked into FLT3 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity profiling of compound <b>18</b>. (A) KinomeScan profiling of compound <b>18</b> at a concentration of 1 μM against 468 kinases. (B) Kinases showed strong binding to compound 18 (less than 1% activity remaining comparing to DMSO control in the assay format with 1 μM <b>18</b>). (C) ADP-Glo biochemical characterization of compound <b>18</b> against FLT3 kinase, BTK kinase, and c-KIT kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>18</b> inhibited FLT3 kinase mediated signaling pathway in MV4-11, MOLM13, and MOLM14 cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>18</b> arrested cell cycle progression and induction of apoptosis in MV4-11, MOML14, and MOLM13 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>18</b>’s antitumor efficacy in MV4-11 xenograft model. Female nu/nu mice bearing established MV4-11 tumor xenografts were treated with <b>18</b> at 12.5, 25.0, 50.0 (mg/kg)/d or with vehicle. Daily oral administration was initiated when MV4-11 tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained five animals. Data are the mean ± SEM. (A) Body weight and <b>(</b>B<b>)</b> tumor size measurements from MV4-11 xenograft mice after <b>18</b> administration. Initial body weight and tumor size were set as 100%. (C<b>)</b> Representative photographs of tumors in each group after 12.5, 25.0, or 50.0 (mg/kg)/d <b>18</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 22-day treatment period. Numbers in columns indicate the mean tumor weight in each group. ns, <i>p</i> > 0.05, (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0013.jpeg" id="rightTab-GRAPHIC-d87e1537-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, NIS, 80 °C, 8 h; (b) DMF/H<sub>2</sub>O, Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, (4-phenoxyphenyl)boronic acid, 120 °C, 12 h; (c) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h; (d) 4 N HCl in EtOAc, rt, 1 h; (e) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypyrrolidine-1-carboxylate, 0 °C to rt, 12 h; (f) THF, triphenylphosphine, DIAD, <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0014.jpeg" id="rightTab-GRAPHIC-d87e1932-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) bis(pinacolato)diboron, 1,4-dioxane, KOAc, Pd(dppf)Cl<sub>2,</sub> 100 °C, 12 h; (b) THF, triphenylphosphine, DIAD, (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypiperidine-1-carboxylate, 0 °C to rt, 12 h; (c) 1,4-dioxane/H<sub>2</sub>O, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 100 °C, 12 h; (d) 4 N HCl in EtOAc, rt, 1 h.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0015.jpeg" id="rightTab-GRAPHIC-d87e2262-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: RC(O)Cl or RSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: RCOOH, HATU, DIEA, DMF, 30 min. Method C: (i) <i>N</i>-Boc-AA-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0016.jpeg" id="rightTab-GRAPHIC-d87e2281-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: MeSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: 2-(dimethylamino)acetic acid, HATU, DIEA, DMF, 30 min. Method C: (i) <i>N</i>-Boc-AA-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/medium/jm-2015-01611e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0017.jpeg" id="rightTab-GRAPHIC-d87e2300-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-24/acs.jmedchem.5b01611/20151218/images/large/jm-2015-01611e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01611&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. Method A: MeSO<sub>2</sub>Cl, DIEA, DCM, 10 min. Method B: 2-(dimethylamino)acetic acid, HATU, DIEA, DMF, 30 min; Method C: (i) <i>N</i>-Boc-(D)Leu-OH, HATU, DIEA, DMF, 30 min, (ii) 4 N HCl in EtOAc, 30 min.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lowenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span> </span><span class="NLM_article-title">Acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1062</span><span class="refDoi"> DOI: 10.1056/NEJM199909303411407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1056%2FNEJM199909303411407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10502596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1051-1062&author=B.+Lowenbergauthor=J.+R.+Downingauthor=A.+Burnett&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJM199909303411407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukemia</span></div><div class="casAuthors">Lowenberg B; Downing J R; Burnett A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1051-62</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvdpRq9xav842y4bB4mnvYfW6udTcc2eY0J8MTEXxSZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D&md5=7cd5e8c3edc8a431afbad11822153c23</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909303411407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909303411407%26sid%3Dliteratum%253Aachs%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DBurnett%26aufirst%3DA.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D1051%26epage%3D1062%26doi%3D10.1056%2FNEJM199909303411407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">American Cancer Society</span>. <span> </span><span class="NLM_article-title">Cancer Facts & Figures 2013</span>. <span class="NLM_publisher-name">American Cancer Society</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=American+Cancer+Society.+Cancer+Facts+%26+Figures+2013.+American+Cancer+Society%3A+Atlanta%2C+GA%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DCancer%2520Facts%2520%2526%2520Figures%25202013%26pub%3DAmerican%2520Cancer%2520Society%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Markovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span> </span><span class="NLM_article-title">FLT-3: a new focus in the understanding of acute leukemia</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1168</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1016/j.biocel.2004.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1016%2Fj.biocel.2004.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=15778081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlChtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=1168-1172&author=A.+Markovicauthor=K.+L.+MacKenzieauthor=R.+B.+Lock&title=FLT-3%3A+a+new+focus+in+the+understanding+of+acute+leukemia&doi=10.1016%2Fj.biocel.2004.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">FLT-3: a new focus in the understanding of acute leukemia</span></div><div class="casAuthors">Markovic, Ana; MacKenzie, Karen L.; Lock, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1168-1172</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The FMS-like tyrosine kinase-3 (FLT-3), which belongs to the class III receptor tyrosine kinase family, is primarily expressed by hematopoietic cells and plays an important role in hematopoiesis.  FLT-3 is also expressed in the majority of acute leukemias, in which the presence of FLT-3 activating mutations is assocd. with poor prognosis.  Consequently, there has been a recent surge in the development of FLT-3 inhibitors for the mol. targeting of leukemia, and many of these are now in clin. trials.  An improved understanding of how FLT-3 interacts with its ligand, as well as how FLT-3 activating mutations are able to trigger downstream intracellular signaling pathways, will provide greater insight to how small mol. inhibitors may best be utilized and combined with established chemotherapeutic drugs for the management of patients with high-risk acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLss2loIUqOrVg90H21EOLACvtfcHk0ljYEIuu5FWNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlChtLc%253D&md5=e36257ac7cb03ee603de0a87292b6f54</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2004.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2004.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DMarkovic%26aufirst%3DA.%26aulast%3DMacKenzie%26aufirst%3DK.%2BL.%26aulast%3DLock%26aufirst%3DR.%2BB.%26atitle%3DFLT-3%253A%2520a%2520new%2520focus%2520in%2520the%2520understanding%2520of%2520acute%2520leukemia%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2005%26volume%3D37%26spage%3D1168%26epage%3D1172%26doi%3D10.1016%2Fj.biocel.2004.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span><span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0ljYEIuu5FWNiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1532/IJH97.05079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors&doi=10.1532%2FIJH97.05079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0liGzZsSUw4Spw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107%26doi%3D10.1532%2FIJH97.05079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0liGzZsSUw4Spw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yoshimoto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbarzadeh-Tabrizi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocnik, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikushige, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagafuji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akashi, K.</span><span> </span><span class="NLM_article-title">FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">5034</span><span class="NLM_x">–</span> <span class="NLM_lpage">5043</span><span class="refDoi"> DOI: 10.1182/blood-2008-12-196055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2008-12-196055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5034-5043&author=G.+Yoshimotoauthor=T.+Miyamotoauthor=S.+Jabbarzadeh-Tabriziauthor=T.+Iinoauthor=J.+L.+Rocnikauthor=Y.+Kikushigeauthor=Y.+Moriauthor=T.+Shimaauthor=H.+Iwasakiauthor=K.+Takenakaauthor=K.+Nagafujiauthor=S.+Mizunoauthor=H.+Niiroauthor=G.+D.+Gillilandauthor=K.+Akashi&title=FLT3-ITD+up-regulates+MCL-1+to+promote+survival+of+stem+cells+in+acute+myeloid+leukemia+via+FLT3-ITD-specific+STAT5+activation&doi=10.1182%2Fblood-2008-12-196055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-196055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-196055%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DJabbarzadeh-Tabrizi%26aufirst%3DS.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DRocnik%26aufirst%3DJ.%2BL.%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DShima%26aufirst%3DT.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DS.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DGilliland%26aufirst%3DG.%2BD.%26aulast%3DAkashi%26aufirst%3DK.%26atitle%3DFLT3-ITD%2520up-regulates%2520MCL-1%2520to%2520promote%2520survival%2520of%2520stem%2520cells%2520in%2520acute%2520myeloid%2520leukemia%2520via%2520FLT3-ITD-specific%2520STAT5%2520activation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5034%26epage%3D5043%26doi%3D10.1182%2Fblood-2008-12-196055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span><span class="refDoi"> DOI: 10.1182/blood-2002-07-2307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2002-07-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=12531805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2002-07-2307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Abrams, Tinya J.; Yuen, Helene A.; Ngai, Theresa J.; Louie, Sharianne G.; Yee, Kevin W. H.; Wong, Lily M.; Hong, Weiru; Lee, Leslie B.; Town, Ajia; Smolich, Beverly D.; Manning, William C.; Murray, Lesley J.; Heinrich, Michael C.; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3597-3605</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells.  In blasts from acute myelogenous leukemia (AML) patients, 2 classes of FLT3 activating mutations have been identified: internal tandem duplication (ITD) mutations in the juxtamembrane domain (25%-30% of patients) and point mutations in the kinase domain activation loop (7%-8% of patients).  FLT3-ITD mutations are the most common mol. defect identified in AML and have been shown to be an independent prognostic factor for decreased survival.  FLT3-ITD is therefore an attractive mol. target for therapy.  SU11248 is a recently described selective inhibitor with selectivity for split kinase domain RTKs, including platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and KIT.  We show that SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation assays.  SU11248 inhibits FLT3-driven phosphorylation and induces apoptosis in vitro.  In addn., SU11248 inhibits FLT3-induced VEGF prodn.  The in vivo efficacy of SU11248 was investigated in 2 FLT3-ITD models: a s.c. tumor xenograft model and a bone marrow engraftment model.  We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the s.c. tumor xenograft model and prolongs survival in the bone marrow engraftment model.  Pharmacokinetic and pharmacodynamic anal. in s.c. tumors showed that a single administration of an efficacious drug dose potently inhibits FLT3-ITD phosphorylation for up to 16 h following a single dose.  These results suggest that further exploration of SU11248 activity in AML patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmUcmQRlrUD7Vg90H21EOLACvtfcHk0liGzZsSUw4Spw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1aqtrs%253D&md5=f996fe320ccf9449951baf97e372c694</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-07-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-07-2307%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605%26doi%3D10.1182%2Fblood-2002-07-2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1093/jnci/djm328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quintas-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia&doi=10.1093%2Fjnci%2Fdjm328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0lhIs8cQpqafFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198%26doi%3D10.1093%2Fjnci%2Fdjm328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S89</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=S89-90&issue=Suppl.+1&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=A.+Yapauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=PKC+412+FLT3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520FLT3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26issue%3DSuppl.%25201%26spage%3DS89%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span><span class="refDoi"> DOI: 10.1182/blood-2003-11-3775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2003-11-3775" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia&doi=10.1182%2Fblood-2003-11-3775"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-11-3775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-11-3775%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676%26doi%3D10.1182%2Fblood-2003-11-3775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaros, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7031</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span><span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0liAJt0XPJkauA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1182/blood-2006-02-005702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.+M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics&doi=10.1182%2Fblood-2006-02-005702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0liAJt0XPJkauA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.%2BM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681%26doi%3D10.1182%2Fblood-2006-02-005702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span><span class="refDoi"> DOI: 10.1182/blood-2009-01-199307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2009-01-199307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation&doi=10.1182%2Fblood-2009-01-199307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-01-199307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-01-199307%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617%26doi%3D10.1182%2Fblood-2009-01-199307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenreid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deignan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huard, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizerman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMinn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalic, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattabiraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragains, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchomel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickramasinghe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lgSiTDWlHZK9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeschke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogan, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5319</span><span class="NLM_x">–</span> <span class="NLM_lpage">5324</span><span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugitaauthor=M.+Carrollauthor=S.+C.+Koganauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0lgSiTDWlHZK9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendleton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bashir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carias, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matusow, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+Overriding+the+Structural+Mechanism+of+the+Quizartinib-Resistant+FLT3+%E2%80%9CGatekeeper%E2%80%9D+F691L+Mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0liPRHWcyXxFJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520Overriding%2520the%2520Structural%2520Mechanism%2520of%2520the%2520Quizartinib-Resistant%2520FLT3%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520F691L%2520Mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Warkentin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A. Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Overcoming Myelosuppression Due to Synthetic Lethal Toxicity in FLT3-Targeted Acute Myeloid Leukemia Therapy</span> <span class="citation_source-journal">eLife</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="refDoi"> DOI: 10.7554/eLife.03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.7554%2FeLife.03445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=3&author=A.+A.+Warkentinauthor=M.+S.+Lopezauthor=E.+A.+Lasaterauthor=K.+Linauthor=B.+L.+Heauthor=A.+Y.+H.+Leungauthor=C.+C.+Smithauthor=N.+P.+Shahauthor=K.+M.+Shokat&title=Overcoming+Myelosuppression+Due+to+Synthetic+Lethal+Toxicity+in+FLT3-Targeted+Acute+Myeloid+Leukemia+Therapy&doi=10.7554%2FeLife.03445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.7554%2FeLife.03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.03445%26sid%3Dliteratum%253Aachs%26aulast%3DWarkentin%26aufirst%3DA.%2BA.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DB.%2BL.%26aulast%3DLeung%26aufirst%3DA.%2BY.%2BH.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DOvercoming%2520Myelosuppression%2520Due%2520to%2520Synthetic%2520Lethal%2520Toxicity%2520in%2520FLT3-Targeted%2520Acute%2520Myeloid%2520Leukemia%2520Therapy%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3D3%26doi%3D10.7554%2FeLife.03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3286</span><span class="NLM_x">–</span> <span class="NLM_lpage">3293</span><span class="refDoi"> DOI: 10.1182/blood-2010-01-266742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1182%2Fblood-2010-01-266742" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3286-3293&author=T.+Satoauthor=X.+Yangauthor=S.+Knapperauthor=P.+Whiteauthor=B.+D.+Smithauthor=S.+Galkinauthor=D.+Smallauthor=A.+Burnettauthor=M.+Levis&title=FLT3+ligand+impedes+the+efficacy+of+FLT3+inhibitors+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-266742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-266742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-266742%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGalkin%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%2520ligand%2520impedes%2520the%2520efficacy%2520of%2520FLT3%2520inhibitors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D3286%26epage%3D3293%26doi%3D10.1182%2Fblood-2010-01-266742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. S.</span><span> </span><span class="NLM_article-title">A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib</span> <span class="citation_source-journal">J. Oncol. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1177/1078155214561281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1177%2F1078155214561281" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+S.+Leeauthor=M.+A.+Rattuauthor=S.+S.+Kim&title=A+review+of+a+novel%2C+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+ibrutinib&doi=10.1177%2F1078155214561281"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F1078155214561281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155214561281%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DRattu%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BS.%26atitle%3DA%2520review%2520of%2520a%2520novel%252C%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520ibrutinib%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2014%26doi%3D10.1177%2F1078155214561281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span> </span><span class="NLM_article-title">Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1038/leu.2015.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1038%2Fleu.2015.175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Wuauthor=C.+Huauthor=A.+Wangauthor=E.+L.+Weisbergauthor=W.+Wangauthor=C.+Chenauthor=Z.+Zhaoauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=A.+Nonamiauthor=L.+Wangauthor=B.+Wangauthor=R.+M.+Stoneauthor=S.+Liuauthor=J.+D.+Griffinauthor=Q.+Liu&title=Ibrutinib+selectively+targets+FLT3-ITD+in+mutant+FLT3-positive+AML&doi=10.1038%2Fleu.2015.175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.175%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520targets%2520FLT3-ITD%2520in%2520mutant%2520FLT3-positive%2520AML%26jtitle%3DLeukemia%26date%3D2015%26doi%3D10.1038%2Fleu.2015.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lhpIB2ECZXUpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>TINKER Molecular Modeling. TINKER—Software Tools for Molecular Design. <a href="http://dasher.wustl.edu/tinker/" class="extLink">http://dasher.wustl.edu/tinker/</a> (updated May 12,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=TINKER+Molecular+Modeling.+TINKER%E2%80%94Software+Tools+for+Molecular+Design.+http%3A%2F%2Fdasher.wustl.edu%2Ftinker%2F+%28updated+May+12%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strockbine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmerling, C.</span><span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of α-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./ψ dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./ψ dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0lhpIB2ECZXUpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Morris, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halliday, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belew, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1639</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;key=1%3ACAS%3A528%3ADyaK1cXntFemur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=1639-1662&author=G.+M.+Morrisauthor=D.+S.+Goodsellauthor=R.+S.+Hallidayauthor=R.+Hueyauthor=W.+E.+Hartauthor=R.+K.+Belewauthor=A.+J.+Olson&title=Automated+docking+using+a+Lamarckian+genetic+algorithm+and+an+empirical+binding+free+energy+function&doi=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function</span></div><div class="casAuthors">Morris, Garrett M.; Goodsell, David S.; Halliday, Robert S.; Huey, Ruth; Hart, William E.; Belew, Richard K.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1639-1662</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review, with 81 refs.  A novel and robust automated docking method that predicts the bound conformations of flexible ligands to macromol. targets has been developed and tested, in combination with a new scoring function that ests. the free energy change upon binding.  Interestingly, this method applies a Lamarckian model of genetics, in which environmental adaptations of an individual's phenotype are reverse transcribed into its genotype and become heritable traits (sic).  We consider three search methods, Monte Carlo simulated annealing, a traditional genetic algorithm, and the Lamarckian genetic algorithm, and compare their performance in dockings of seven protein-ligand test systems having known three-dimensional structure.  We show that both the traditional and Lamarckian genetic algorithms can handle ligands with more degrees of freedom than the simulated annealing method used in earlier versions of AuToDOCK, and that the Lamarckian genetic algorithm is the most efficient, reliable, and successful of the three.  The empirical free energy function was calibrated using a set of 30 structurally known protein-ligand complexes with exptl. detd. binding consts.  Linear regression anal. of the obsd. binding consts. in terms of a wide variety of structure-derived mol. properties was performed.  The final model had a residual std. error of 9.11 kJ mol-1 (2.177 kcal mol-1) and was chosen as the new energy function.  The new search methods and empirical free energy function are available in AUTODOCK, version 3.0.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXZfPvnZWcbVg90H21EOLACvtfcHk0lhmLjq1K6pu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFemur4%253D&md5=804b9f797c0b2cf942444c17b5653659</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-987X%252819981115%252919%253A14%253C1639%253A%253AAID-JCC10%253E3.0.CO%253B2-B%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DHalliday%26aufirst%3DR.%2BS.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DW.%2BE.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutomated%2520docking%2520using%2520a%2520Lamarckian%2520genetic%2520algorithm%2520and%2520an%2520empirical%2520binding%2520free%2520energy%2520function%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1998%26volume%3D19%26spage%3D1639%26epage%3D1662%26doi%3D10.1002%2F%28SICI%291096-987X%2819981115%2919%3A14%3C1639%3A%3AAID-JCC10%3E3.0.CO%3B2-B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN','PDB','3GEN'); return false;">PDB: 3GEN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d87e4746-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i64"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01611">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45560"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01611">10.1021/acs.jmedchem.5b01611</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding data of compound <b>18</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01611/suppl_file/jm5b01611_si_001.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01611/suppl_file/jm5b01611_si_001.xlsx">jm5b01611_si_001.xlsx (497.87 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-24%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01611" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01611" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677af7aa6b0f32d7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
